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Alternative Targets for the Treatment of Stroke
Craig T. Ajmo, Jr.
ABSTRACT
Stroke is cerebrovascular injury that has been reported to be the third
leading cause of death and the first leading cause of disability in the world (W. H.
O. 2007). Currently, there is only one FDA approved treatment for stroke which
is recombinant tissue plasminogen activator. This treatment has a narrow
therapeutic window of three hours after ischemic stroke and can adversely cause
the production of oxygen free radicals and intracranial hemorrhage. These
limitations result in only 2-3% of all stroke victims as being candidates for this
therapy as many patients do not arrive at the hospital in time to receive
treatment, are not properly diagnosed, or do not know that they have had a
stroke within this three hour time period. The purpose of these experiments was
to elucidate alternative targets of stroke for the benefit of developing new
treatments that stimulate neuroprotective and anti-inflammatory effects at the site
of injury. It has been shown that transfusion of human umbilical cord blood cells
up to 48 hours after stroke significantly reduces infarction and we have examined
other targets that mimic these effects. We have shown that sigma receptor
activation by DTG, a high affinity universal sigma agonist, reduces infarct volume
when administered 24 hours after stroke. This suggests that modulation of
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neurodegenerative and inflammatory responses can extend the therapeutic
window of treatment. For the first time, evidence is provided that shows that the
spleen enhances the neurodegeneration caused by stroke as splenectomy prior
to stroke profoundly decreased infarction volume. Finally, we studied signaling
mechanisms of the splenic reaction to stroke and determined that this response
is not directly dependent on neurotransmission via the splenic nerve.
Denervation of the spleen prior to stroke showed no changes in
neurodegenerative load at the site of injury in rat brains when compared to those
subjected to stroke only. Overall, these experiments provide evidence showing
that targets mediating neuroprotective and anti-inflammatory effects can lead to
novel therapeutic interventions of stroke.
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INTRODUCTION
Stroke
Stroke is a cerebrovascular injury that is the result of the obstruction or
hemorrhagic interruption of blood flow to the brain causing damage to the
cerebral tissue. Annually, 15 million people worldwide suffer a stroke. Of these,
5 million die and another 5 million are left permanently disabled, placing a burden
on family and community making this injury the third leading cause of death and
first leading cause of disability in the world. The major risk factors for stroke are
similar to those for coronary heart disease, with high blood pressure and tobacco
use the most significant modifiable risks. Atrial fibrillation, heart failure and heart
attack are other important risk factors (World Health Organization 2007).
Stroke carries a high risk of death and survivors can experience loss of
vision and/or speech, paralysis, and confusion. Even with advances in
technology and facilities, 60% of those who suffer a stroke die or become
dependent (W.H.O. 2007). In 2004 The American Heart Association estimated
that the direct and indirect costs of stroke are 53.6 million dollars (American
Heart Association 2007). Based on these statistics and costs, stroke needs to be
a main concern for researchers and health care providers for the purpose of
developing novel treatments as well as reducing the risk factors that increase the
chances of this cerebral injury.
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Stroke Health Risks
There are several health risks that can increase the incidence of stroke in
an individual. Some health risks can not be changed which are a function of
heredity. Those threats that can not be changed revolve around age, heredity,
sex, and prior stroke. However, the majority of the causes of stroke are based
on personal lifestyle and can be altered with proper knowledge. The chance of
stroke more than doubles for each decade of life after the age of 55 and people
who have had parents or grandparents that have suffered a stroke are also at
higher risk. Heredity is also an issue of stroke resulting from race. Blacks have
a higher risk than Caucasians partly because of higher risks of high blood
pressure, diabetes and high blood pressure in this group. Gender is a factor in
that men are more likely to have a stroke than women. However, more than half
of all total stroke deaths occur in women (A.H.A 2007).
Risk factors that can be monitored and altered are very similar to those for
coronary heart disease. High blood pressure, smoking, diabetes, high
cholesterol, poor diet, obesity and physical inactivity can all lead to stroke.
Physical defects in the circulatory system are problematic but are also treatable.
Atrial fibrillation, a heart rhythm disorder, can result in the pooling of blood and
clot formation at the atria. Carotid and other artery diseases are caused by the
narrowing of arteries by fatty deposits from atherosclerosis. These fatty deposits
can eventually break free and cause vessel blockage. These risk factors all have
the potential of instigating one of the types of stroke and need to be routinely
monitored so as to inhibit such an injury.
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Types of Stroke
There are two main types of stroke that occur, hemorrhagic which is blood
vessel rupture and ischemic caused by blockage of a blood vessel. There are
two subclasses of hemorrhagic stroke, subarachnoid and cerebral hemorrhage.
Subarachnoid hemorrhage occurs when a blood vessel on the brain’s surface
ruptures and bleeds into the space between the skull and brain. Cerebral
hemorrhage is the rupturing of a blood vessel inside the brain. This results in the
flooding of the surrounding cerebral tissue with blood.
Subarachnoid or cerebral hemorrhage results in the loss of a constant
blood supply such that the cells of the brain are no longer obtaining the nutrients
and oxygen they need to continue to function. Pooled blood from the hemorrhage
can also put pressure on surrounding brain tissue and interfere with brain
function (A.H.A 2007). The amount of bleeding establishes the harshness of the
cerebral hemorrhages. Typically, people with cerebral hemorrhages die of
increased pressure on their brains; however pressure from the blood compresses
part of the brain. If the person survives, gradually the pressure goes away. Then
the brain may regain some of its former function (A.H.A 2007).
Ischemic stroke is the most common type of stroke accounting for 88% of
all reported stroke incidents and is the main focus of the following studies. This
type of stroke occurs when a thrombus, a blood clot that forms in a blood vessel,
blocks blood flow in an artery bringing blood to part of the brain. When the blood
clot forms within an artery of the brain, it's called a cerebral thrombotic stroke.
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An embolus, a plaque that is formed elsewhere in the body, may also cause an
ischemic stroke. The embolus is carried by the bloodstream until it becomes
lodged in an artery leading to or in the brain and is referred to as a cerebral
embolism (A.H.A 2007).

The Infarction
Blockage of an artery leading to the brain by an embolus or thrombus
inhibits blood flow bringing oxygen and nutrients to the cells of the tissue.

This

lack of sustenance results in two areas of expanding damage surrounding the
artery or arteries that are no longer being perfused with blood. The first region
directly adjacent to those arteries is the core ischemic region, which is widely
considered to be an area of irreversible cell death. At the ischemic core, drastic
changes in physiology, biochemistry, and energy metabolism occur (Lipton
1999). Almost immediately after blood perfusion inhibition, there is a rapid
depolarization within brain cells leading to an increase of extracellular K+ and a
large influx of Ca2+ into the cells. Levels of adenosine triphosphate (ATP) at the
core drop markedly to approximately 25% showing arrested metabolism (Lipton
1999). Reactive oxygen species are also present at the central region and can
be produced by a variety of mechanisms including glutamate excitation,
intracellular calcium overload, mitochondrial cytochrome C release, nitric oxide
synthatase, caspase activation, and xanthine oxidase (Dirnagl et al. 1999; Lewen
et al. 2000). Damage is caused at the core ischemic region as a result of these
reactive oxygen species, but because the ischemic core has little or no blood
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flow, the levels of oxygen free radicals are less than at the penumbra, the region
surrounding the ischemic core (Dirnagl et al. 1999).
The penumbra is classified as a functionally impaired yet still viable tissue
region surrounding the ischemic core as it receives minor amounts of blood
perfusion from collateral arteries (Bandera et al. 2006). The penumbra is central
to most stroke-related investigations as the penumbra contains areas that have
the potential of recovering if appropriate treatment is administered. Physiology,
biochemistry, and energy metabolism alterations occur at a slower rate than in
the core but the progression of these alterations will eventually lead to the same
cellular fate as the core. Within the penumbra there are no rapid depolarizations.
However, sporadic transient depolarizations (Ginsberg and Pulsinelli 1994; Mies
et al. 1991). are much more common in the penumbra and are dependent on
glutamate release from the infarct core (Lipton 1999). ATP levels are maintained
at approximately 50-70% of base levels and glucose utilization becomes elevated
in the penumbra at the early stages of the ischemic insult but fall off to
approximately 50% of base levels, equal to the core, by 3.5 hours after stroke
(Yao et al. 1995). Cell death eventually follows in the penumbra due to the
failure of energy (ATP) production, glutamate-mediated toxicity with influx of Na+
and Ca2+, and mitochondrial failure.
Neurodegeneration
Neurodegeneration is characterized by the loss of neuron function and
eventually cell death. Degeneration and neuronal cell death occur through
necrotic and apoptotic mechanisms (Weinberger 2006). Necrosis is
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characterized by the disruption of cellular homeostasis with nuclear dissolution,
membrane dysfunction, cell swelling, and severe mitochondrial damage
(Bhardwaj et al. 2003; Choi 1992). Excessive release of excitatory
neurotransmitters such as glutamate (Park et al. 1988; Wu and Fujikawa 2002)
results in an increased activation of the glutamate receptors α-amino-3-hydroxy5-methlyl-4-isozazolone-proprionic acid (AMPA)., receptors which increase
sodium uptake by the neurons (Endres and Dirnagl 2002) and N-methly-Daspartate (NMDA)., receptors that cause an influx of intracellular calcium (Ientile
et al. 2002; Kahn et al. 1997). While sodium and calcium exchange pumps are
able to remove some of the calcium that has entered the cells, three sodium ions
enter for every two calcium ions that are removed. This results in edema or cell
swelling as water is retained by the osmotic imbalance (Rosenberg 1999).
Energy requiring calcium pumps fail as ATP levels fall, adding to the calcium
levels in the cells (Rosenberg 1999). The increase of intracellular calcium
resulting from glutamate excitotoxicity will eventually lead to the activation of
proteases, such as caspases and matrix metalloproteinases, which cause
irreversible damage to cellular membranes and DNA (White et al. 2000). Cells
are unable to respond to proteolytic injury and die (White et al. 2000).
Besides calcium toxicity, NMDA activation by glutamate also leads to the
production of the free radical nitric oxide (NO). After the activation of NMDA
receptors, calcium is transiently increased in the cytosol and forms a complex
with calmodulin (Moncada and Bolanos 2006). This complex binds to and
activates constitutive neuronal nitric oxide synthase (nNOS) (Moncada and
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Bolanos 2006). The nNOS will then produce NO through enzymatic oxidation of
the guanidino group of L-arginine in the presence of O2, NADPH and
tetrahydrobiopterin (Marletta et al. 1998). Peroxynitrite, a free oxygen
metabolite, is eventually formed when NO and superoxide anion react (Beckman
and Koppenol 1996). Superoxide anions are a byproduct of mitochondrial
respiration and are constantly produced in conjunction with NADPH oxidases
(Virag et al. 2003). Peroxynitrite initiates lipid peroxidation, causes DNA
breakage and reacts with thiols (Radi et al. 1991; Salgo et al. 1995a; Salgo et al.
1995b). Cells are again incapable of repairing this damage and die.
Catecholamines are neurotransmitters that contribute to the necrosis of
neurons by being excessively released at the time of stroke. Ischemic events
inhibit the uptake of the neurotransmitters resulting in a build up of
catecholamines outside the cells (Weinberger and Cohen 1982; Weinberger et
al. 1985). Dopamine, a catecholamine that acts as a neurotransmitter in the
central nervous system, is released at the time of initial ischemic event and is
converted to dihydroxyphenylacetic acid (DOPAC) (Weinberger and Nieves-Rosa
1987). The formation of DOPAC results in the production of hydrogen peroxide
which forms reactive oxygen species. These reactive oxygen species cause lipid
peroxidation and denature proteins resulting in the necrosis of the neuropil, the
unmyelinated neuronal processes of the neurons, in the infarction (Rabinovic et
al. 2000).
Apoptotic cellular death occurs mainly in the penumbra of the infarction. It
is a process defined as a self-destructive cell death that involves activation of

7

mechanisms encoded in the genomes of all higher eukaryotes and identified by
chromatin condensation and increased mitochondria membrane permeability
(Weinberger 2006). Compared to necrosis, there is no cell membrane and
mitochondria disruption and there in no inflammation or injury to surrounding
tissue (Johnson et al. 1995; Kerr et al. 1972). Although there is no inflammation
in surrounding tissue, inflammatory mediators such as the cytokine tumor
necrosis factor alpha (TNF-α) play an initial role in the events that lead to
apoptosis (Hallenbeck 2002). Cytokines are increased within hours of the initial
insult and result from immediate early gene products, such as c-fos and c-jun,
activating transcription sites of the cytokine genes (Rosenberg 1999). TNF-α
initiates apoptotic pathways by activating the cell membrane bound TNF
receptors immediately starting caspase cascades. Activation of this receptor
also results in mitochondria-mediated apoptosis by stimulating the production of
Bid, a proapoptotic Bcl-2 family member. Bid then activates Bax, another Bcl-2
family member, which localizes to the mitochondrial membrane increasing its
permeability. Translocation of these Bcl-2 members into the permeable
membrane of the mitochondria induces cytochrome c release. Cytochrome c
promotes the activation of procaspase-9 which allows caspase-9 to activate
caspase-3. Caspase-3 causes irreparable DNA damage leading to apoptosis
(Atlante et al. 2003; Zukin et al. 2004).
Inflammation: Peripheral Immune Cell Response
Inflammation is the complex biological response of the body to harmful
stimuli and in the case of stroke is the response of the brain parenchyma to
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insult. It is typically characterized by the infiltration of leukocytes, which in the
case of cerebral ischemia are mainly polymorphonuclear leukocytes including
neutrophils, monocytes/macrophages, lymphocytes and the activation of
microglia, the resident immune cells of the brain (Kochanek and Hallenbeck
1992). Astrocytes, neuronal support cells, also contribute to inflammation during
insult (Ridet et al. 1997). The collective action of these immune and neuronal
support cells is to remove damaged tissue, but they have the potential to
enhance infarction expansion ultimately resulting in more damage in the brain. In
response to ischemia, transcription factors of brain cells produce inflammatory
proteins that orchestrate necrosis and apoptosis (Feuerstein 2006). After
interruption of cerebral blood flow, tissue injury begins with an inflammatory
reaction. This reaction requires the infiltration of leukocytes, neutrophils and
macrophages, which are the cellular mediators of subsequent microvessel
obstruction, edema formation, cellular necrosis, and tissue infarction (Chou et al.
2004; Clark et al. 1993). Intervention of this reaction can reduce the deleterious
effects that result from the inflammatory response. Studies have shown that
post-ischemic administration of antibodies directed against adhesion molecules
and infiltrating monocytes/macrophages, such as CD11b/CD18 and ED1
respectively, reduce ischemic cell damage and apoptosis in rats subjected to
transient MCAO (Chopp et al. 1996; Chopp et al. 1994; Zhang et al. 1995a;
Zhang et al. 1994b; Zhang et al. 1995b).
Leukocytes circulate in the bloodstream and enter the tissues only when
they are recruited to sites of infection or inflammation. Under normal conditions
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neutrophils do not interact closely with the cerebral endothelium. However, as a
result of blood flow obstruction, these cells are the first inflammatory peripheral
cell type present in the infarction (Kochanek and Hallenbeck 1992). Accumulation
of these cells begins within three hours at the site of injury and peaks at about 24
hours after infarction. Afterwards the number of neutrophils declines (Pantoni et
al. 1998). Neutrophil infiltration is preceded by increased expression of cytokineinduced neutrophil chemoattractant (CINC). Migration to the site of injury in
response to CINC results in binding of neutrophils to the endothelial cells. This
accumulation of neutrophils impedes blood vessels causing further obstruction of
blood flow extending the infarction (Pantoni et al. 1998). Increased expression of
CINC mRNA has been detected in the cortex and caudate putamen in rat brains
injured by ischemia as early as 6 hours (Yamasaki et al. 1995). Evidence that
shows that CINC attracts neutrophils to ischemic damage comes from transient
stroke rodent experiments that show that CINC is detectable in brain tissue
before neutrophil infiltration at three hours after reperfusion (Yamasaki et al.
1995). Once attracted to endothelial and brain cells, neutrophils incite tissue
damage through the release of oxygen-free radicals, cytokines, and proteolytic
enzymes (Akopov et al. 1996; Barone and Feuerstein 1999; Emerich et al. 2002;
Zhang et al. 1994a). In addition, neutrophils have also been implicated in
ischemic injury as a source of MMP-9, a protease that degrades the basal lamina
and mediates breakdown of the blood brain barrier after injury (Justicia et al.
2003).

10

Monocytes/macrophages are the most abundant leukocyte that enters the
brain after focal cerebral ischemia (Stoll et al. 1998). These cells contribute to
inflammation and infarction by releasing vasoconstrictive mediators
(superoxidase anions)., cytokines, free oxygen radicals, NO, and proteolytic
enzymes that damage cell membranes, alter the blood brain barrier, and
contribute to post-ischemic edema (Feuerstein 2006; Geng 1997; Hendriks et al.
2005; Laffi et al. 1995). Permanent middle cerebral artery occlusion (MCAO)
causes monocytes/macrophages to start infiltrating the parenchyma at 12 hours
after injury (Clark et al. 1993). Once in the parenchyma
monocytes/macrophages become indistinguishable from microglia, the resident
macrophages of the brain, based on morphological grounds, the expression of
the same immunocytochemical markers and performing the same inflammatory
actions during stroke (Stoll et al. 1998). Monocyte/macrophage infiltration is
preceded by the expression of monocyte chemoattractant protein-1 (MCP-1).
This chemoattractant expression has been reported to be found early after
MCAO, MCP-1 mRNA increases six hours after MCAO and remains elevated up
to 5 days after injury (Yamasaki et al. 1995). Studies have localized MCP-1
expression at early stages of ischemic injury to endothelial cells, astrocytes, and
microglia (Wang et al. 1995).
While the inflammatory response that occurs after stroke is antigen
nonspecific and mediated by the innate immune system, there is an antigen
nonspecific inflammatory response mediated by lymphocytes as well (Gee et al.
2007). Breaching of the blood brain barrier allows the adaptive immune system
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to encounter novel central nervous antigens (Gee et al. 2007). In the brain
neutrophils are the first leukocytes to accumulate and infiltrate the parenchyma,
followed by monocytes and then T lymphocytes (Schroeter et al. 1994).
Although data supporting the role of T cells is limited, there is evidence that T
lymphocyte infiltration occurs at the early phase of ischemia and accompanies
neutrophil and macrophage infiltration (Jander et al. 1995; Schroeter et al. 1994;
Schwab et al. 2001; Vendrame et al. 2005). Studies suggest that T cells work in
vascular beds to recruit other leukocyte subsets, release inflammatory cytokines
and attack antigens found in myelin sheaths which result in demyelination of
neurons (Gee et al. 2007; Yilmaz et al. 2006; Zipp and Aktas 2006). Relatively
little information is known about the actions of B cells in ischemia (Yilmaz et al.
2006). Flow cytometry analysis of ipsilateral hemisphere brain homogenates
show increased presence of the B cell membrane molecular marker
CD45+/CD11b+ from rats subjected to MCAO (Vendrame et al. 2005). Recent
studies have shown that B cells contribute to ischemia/reperfusion injury in the
kidneys through release of soluble factors and are independent of neutrophil,
macrophage, and T cell recruitment (Yilmaz et al. 2006). This suggests that B
cells contribute to the overall damage occurring in the brain after stroke and must
be investigated further.

Inflammation: Resident Immune Cell Response and Astrogliosis
In the resident immune response of the brain, microglia, which arise from
peripheral mesoderm (Chan et al. 2007), are the first cells to respond to cerebral
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ischemia (Lai and Todd 2006). Microglia are resident brain macrophages that
adopt a typical ramified morphology in the central nervous system environment
(Stoll et al. 1998). In response to pathogens, microglia exert a multiple of
functions including transformation into phagocytes, presenting antigens to T
cells, or producing neurotoxic factors for pathogen removal (Stoll et al. 1998).
Under extreme brain injury conditions, such as ischemia, microglia become over
activated inducing significant and high detrimental neurotoxic effects by the
excess production of cytotoxic factors such as superoxide, NO, and TNF-α
(Danton and Dietrich 2003; Dirnagl et al. 1999; Polazzi and Contestabile 2002).
Activation of these cells by pathogens or injury is also accompanied by
morphological transition with the loss of the ramified appearance and the
microglia taking on a more amoeboid shape (Stoll et al. 1998). At the time of
stroke, microglia have also been shown to be involved in neuroprotection by
releasing neurotropins, and growth hormones, as well as aid in glutamate reuptake which reduces necrotic and apoptotic cascades (Lai and Todd 2006).
Recent evidence continues to support the neuroprotective role of microglia.
Selective ablation of the proliferation of microglial cells during ischemic injury
actually increases infarct damage in the brain of transgenic mice (LalancetteHebert et al. 2007).
Astrocytes, brain cells of neuroectodermal origin, also respond to ischemic
injury (Mucke and Eddleston 1993). Under normal conditions, astrocytes perform
several functions that are essential for normal neuronal activity, including
glutamate uptake, glutamate release, K+ and H+ buffering, and metabolic and
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trophic support (Swanson et al. 2004). In response to injury, astrocytes undergo
morphological changes resulting in elongated processes and up-regulate
intermediate filament proteins, particularly glial fibrillary acidic protein (GFAP)
(Swanson et al. 2004). When these cells exhibit these changes the astrocytes
are referred to as reactive and this is perhaps the best known hallmark of gliosis
(Pekny and Nilsson 2005). Reactive gliosis is characterized by the hypertrophy
of astrocytes and proliferation of both astrocytes and microglial cells around the
injured region forming the glial scar (Ridet et al. 1997). Reactive astrocytes
produce and release inflammatory mediators such as cytokines and chemokines.
These mediators will increase the inflammatory effects at the site of injury by
activating necrotic/apoptotic pathways and aiding in inflammatory cell recruitment
(Ridet et al. 1997). Astrocytes also amplify inflammation and neurodegeneration
by releasing glutamate, reducing glutamate uptake, and secreting nitric oxide
(Swanson et al. 2004).

Inflammation: Biochemical Mediators of Stroke
In response to ischemia in the brain, immune and injury response cells
transcribe inflammatory mediators that coordinate the biochemical pathways of
stroke. Such mediators include cytokines, chemokines, adhesion molecules,
lipid mediators and kinins. The uninjured brain has virtually no or extremely low
levels of expression of the above mentioned mediators, but in response to
ischemic injury, these molecules become highly expressed (Pantoni et al. 1998).

14

Pro-inflammatory cytokines, which include interleukins, are low molecular
weight glycoproteins that act as intercellular messengers and are produced by
macrophages, monocytes, lymphocytes, endothelial cells, fibroblasts, platelets,
and many other cell types (Pantoni et al. 1998). These cytokines have various
functions during cerebral ischemia and act at low concentrations on specific
target cell receptors, whose expression is also mediated by the cytokines
(Pantoni et al. 1998). Binding of cytokines to receptors activates protein kinases
and phosphatases which initiate apoptosis through the activation of transcription
factors and DNA damage (Pantoni et al. 1998). Cytokines attract leukocytes to
the site of insult as well as stimulate the synthesis of adhesion molecules in the
invading leukocytes, endothelial, glial, and other cells promoting the inflammatory
response (Pantoni et al. 1998). Cytokines also contribute to ischemic tissue
damage by altering levels of endogenous mediators of thrombogenesis, such as
tissue plasminogen activator (Huang et al. 2006).
There is variation and overlap in the functions of the cytokines in ischemic
injury. IL-1 is an extensively studied cytokine that exits in two forms IL-1α and IL1β. These forms act mainly through two receptors types, type I and II. The type I
receptor is found on a variety of cells and binds both forms of IL-1 with similar
affinity. The type II receptor is found on the cell surface of neutrophils, B
lymphocytes, and macrophages and binds IL-1β with a higher affinity (Buttini et
al. 1994; Dinarello 1996; Huang et al. 2006; Mayadas et al. 1993; Polazzi and
Contestabile 2002; Zhang et al. 1998). IL-1, particularly IL-1β, induces the
expression of ICAM-1, an adhesion molecule on the surface endothelial cells
15

(Kaplanski et al. 1994). The increase of ICAM-1 is presumably a link between
the up-regulation of IL-1 after ischemia and the following influx of neutrophils
(Huang et al. 2006). IL-6 has similar biological activities as IL-1 in the
development of the inflammatory response (Lindsberg et al. 1996) but has also
been shown to induce phospholipase A2 gene expression which stimulates the
production of leukotrienes, prostaglandins, and platelet activating factor, all of
which are involved in ischemic brain damage (Crowl et al. 1991). Like the
interleukins, TNF-α induces the expression of adhesion molecules by glial and
endothelial cells. This promotes neutrophil adherence and accumulation into the
microvasculature (Liu et al. 1994). This cytokine also causes blood brain barrier
alterations, pro-adhesive transformations of endothelial cell surfaces to take hold
of circulating immune cells and glial cell activation to form scars as part of the
repair and remodeling process in response to ischemia (Pantoni et al. 1998).
While TNF-α and IL-1 promote adhesion between endothelial cells and
leukocytes, they are actually poor attractants for leukocytes (Pantoni et al. 1998).
Other chemoattractant cytokines, CINC and MCP-1, are referred to as
“chemokines” and are specifically involved in guiding leukocytes through brain
parenchyma towards the site of ischemic injury (Pantoni et al. 1998).
Chemokines are low molecular weight molecules that share a structural pattern
of four cystine residues (Furie and Randolph 1995). They are divided into two
main families (C-x-C and C-C) according to the presence or absence of an amino
acid between the residues of the two most amino-proximal cystines (Furie and
Randolph 1995). The structural distinction results in different attraction of cells.
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The C-X-C chemokines tend to attract neutrophils, where the C-C chemokines
preferentially act on monocytes/macrophages (Pantoni et al. 1998). Each
cytokine family binds to specific receptors formed by seven transmembrane
domains that activate G proteins. This activation leads to the production of
intracellular protein kinases which activate cellular inflammatory responses
(Gourmala et al. 1997).
Cell adhesion molecules mediate the adhesion of leukocytes to
endothelial cells as well as the immune cell migration from the microvasculature
to the site of injury by a variety of molecules found on the membranes of both
leukocytes and endothelial cells (Pantoni et al. 1998). Adhesion molecules are
divided into three structural classes: (1) selectins, (2) integrins, and (3) proteins
of the immunoglobulin superfamily. Selectins are glycoproteins that mediate lowaffinity endothelial-leukocyte interactions, thus promoting the margination and
rolling of leukocytes along endothelial cells. Integrins are heterodimeric
membrane glycoproteins that play a role in the extracellular matrix and cell-cell
interaction. At the level of the basal lamina, integrins link endothelial cells to
components of the extracellular matrix, such as laminin and collagen. In the
brain, integrins join the endothelial cells, astrocytes, and basal lamina that
comprise the blood brain barrier and are crucial in maintaining the integrity of the
cerebral microvasculature (Haring et al. 1996; Huang et al. 2006). The
immunoglobulin superfamily mediates cell adhesion of leukocytes to endothelia
at low shear forces and creates a stronger attachment compared to the selectins
(Pantoni et al. 1998).
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Lipid mediators of arachidonic acid play a role in the inflammation that is
occurring at the site of injury (Tzeng et al. 2005). Prostaglandins, one subset of
these lipid mediators, are synthesized from arachidonic acid which is produced
from the release of phospholipae A2 (PLA2) (Tzeng et al. 2005). Calcium
accumulation in brain cells by energy failure resulting from loss of blood activates
PLA2 which hydrolyses the release of arachidonic acid from glycerophospholipids
(Chen and Bazan 2005). Prostaglandins are then synthesized from arachidonic
acid and cycloxygenase (COX) enzymes (Tzeng et al. 2005). Prostaglandins
contribute to inflammation by altering the integrity of membranes, disrupt the
activity of ion channels, and inhibit glutamate uptake (Griffin et al. 1994).
Prostaglandins are excessively produced in the brain at the time of injury by
astrocytes and microglia. Astrocytes and microglia respond to pro-inflammatory
cytokines by releasing COX which increases the production of the prostaglandins
and then act as the pro-inflammatory mediators (Tzeng et al. 2005).
Another group of inflammatory lipid mediators synthesized from
arachidonic acid are the leukotrienes (Funk 2005). Production of these
mediators begins at the nuclear membranes of inflammatory cells (macrophages,
neutrophils, and microglia) in response to inflammatory stimuli such as cytokines
(Funk 2001; Henderson 1994; Lewis et al. 1990; Samuelsson 1983). Where
prostaglandin synthesis was dependent on the cycloxygenase enzyme,
leukotriene production is dependent on 5-lipoxygenase (5-LO) which catalyses
the conversion of arachidonic acid to 5-hydroperoxyeicosatetraenoic acid and the
unstable leukotrieneA4 (LTA4) with the aid of the accessory protein 5-LO-
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activating protein (FLAP) (Dixon et al. 1990; Miller et al. 1990). Here, the
pathway branches as LTA4 hyrolase can metabolize LTA4 to leukotriene B4
(LTB4). LTB4 acts as a potent neutrophil chemotaxin, promotes the adhesion of
leukocytes to vascular endothelium and recruits T lymphocytes to sites of
inflammation (Ford-Hutchinson et al. 1980; Gimbrone et al. 1984; Goodarzi et al.
2003; Ott et al. 2003; Radmark et al. 1984). Alternatively, LTA4 can be
conjugated with glutathione to yield a series of leukotrienes known as LTC4,
LTD4, and LTE4 (Samuelsson 1983). Collectively these are referred to as
cysteinyl leukotrienes (CysLT) (Samuelsson 1983). During anaphylactic
reactions, this group of leukotrienes causes airway smooth-muscle contraction
and vascular edema (Funk 2005). Leukotrienes are then secreted into the
extracellular space where they bind to G-protein couple receptors BLT1, BLT2,
CysLT1 and CysLT2. These receptors are expressed on different target cells,
including leukocytes, smooth-muscle cells and endothelial cells (Heise et al.
2000; Lynch et al. 1999; Yokomizo et al. 1997).
Kinins are most known as vasoconstrictors and vasodilators of smooth
muscle, but they have been implicated in inflammatory responses (Couture et al.
2001; Rodi et al. 2005). Kinins bond a specific receptor referred to as the
bradykinin receptor which has two subsets, B1 and B2 (Couture et al. 2001).
During ischemia, B2 receptor activation promotes vascular permeability of
endothelial cells and edema (Dray and Perkins 1993). The pro-inflammatory
effects of B1 receptors include promotion of blood leukocyte migration to the site
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of injury and edema. Besides kinin binding, bradykinin receptors can also be
stimulated by prostaglandins, cytokines, and nitric oxide (Dray 1997).

Current Treatment
Presently there is only one Food and Drug Administration approved drug
for treating stroke which is recombinant tissue plasminogen activator (rtPA)
(Marler and Goldstein 2003). This treatment, however, has several therapeutic
limitations including a three hour therapeutic widow, use only with embolic stroke,
no anti-inflammatory or neuroprotective effects, the risk of causing intracranial
hemorrhage, oxygen free radical production and recurrent stroke (Marler and
Goldstein 2003; NINDS 1995). These limitations result in approximately 2-3% of
all stroke victims being candidates for this therapy as many patients do not arrive
at the hospital to receive treatment, are not properly diagnosed, or even know
that they are having a stroke in this three hour time period. For those individuals
who are candidates for rtPA therapy, only 13% show improved outcomes (Albers
et al. 2004; Albers et al. 1998).

Recombinant Tissue Plasminogen Activator
Recombinant tissue plasminogen activator is a secreted serine protease
which converts the proenzyme plasminogen to plasmin, a fibrinolytic enzyme.
Plasminogen is a glycoprotein produced by the liver and found in blood and most
extravascular fluids. The generation of plasmin occurs preferentially on the fibrin
surface, which offers binding sites for plasminogen and rtPA at the C-terminal
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lysine residues (Chromogenix 1995). This binding stimulates plasminogen
activation, but also localizes the action of plasmin to sites of fibrin formation
which promotes efficient clot lysis. Plasmin can then dissolve a blood clot by
degrading the fibrin polymers of the clot into soluble fragments. If rtPA causes
increased enzymatic activity of the plasmin, hyperfibrinolysis can occur resulting
in excessive bleeding, producing the potential of hemorrhagic stroke (Marx
2004).

Failed Treatments
Presently there are two main strategies in developing new treatments for
embolic stroke; attacking the clot and protecting the neurons that are being
subjected to ischemia. While rtPA had been deemed sufficient for clot busting,
there have been many failed attempts to develop a treatment for stroke that
promotes neuroprotection after ischemia insult. Failures in treatment usually
arise from discrepancies between modeling of cerebral ischemia in animals
compared to clinical trials in human test subjects (del Zoppo 1998). Animal
models become unpredictable for reasons related to incomplete understanding of
the pathophysiology of ischemic stroke, species differences, cellular reactivity,
excessive toxicity, vascular disease processes, inflammation, and the use of
other pharmacological modifiers such as anesthesia (del Zoppo 1998). These
factors are all potential contributors to ischemic tissue injury and assessment of
these may affect other species differently.
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Treatments promoting neuroprotection work to block those pathways that
stimulate necrosis and apoptosis during or after an ischemic insult. The most
notable of these interventions are antagonists of glutamate receptors and
calcium channels. One of the focuses of glutamate receptor antagonists is to
inhibit the actions of the NMDA receptor. Blockage of this receptor results in
reduction of calcium influx into neurons through post synaptic calcium channels
(Hoyte et al. 2004). Clinical testing of this treatment resulted in several adverse
affects. Blockage of the NMDA channels by competitive antagonism required
high concentrations of the antagonist due to the high affinity of the NMDA
receptor to glutamate. High concentrations were also needed to reach effective
concentrations of the antagonist in the penumbra. This, however, led to
hallucinations, delirium, and psychosis (Hoyte et al. 2004). Short neuroprotective
time windows were a concern also because of the development of infarction. In
animal models, there is a slow expansion of damage over the first few days of
injury. Therefore, neuroprotective effects were a result of postponed injury
development. Finally antagonism of glutamate receptor activation needed to
occur very early after ischemia onset making this treatment potentially effective
only within the first hour or less of injury (Hoyte et al. 2004).
Calcium channel blockers have been used in an attempt to promote
neuroprotection in stroke victims by reducing calcium influx by voltage gated
calcium channels. Nimodipine is a specific antagonist of calcium channels that
has been evaluated in neuroprotective studies and works by blocking the L-type
calcium channel (Langley and Sorkin 1989). Unfortunately, this treatment and
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other calcium channel blockers have shown no efficacy in alleviating
neurodegenerative load or behavioral improvements in clinical trials (Horn et al.
2001). These antagonists have also been shown to have adverse effects of
severely lowering blood pressure of stroke victims (Horn et al. 2001).
Anti-inflammatory agents have been investigated as another avenue to
reduce infarct volume. Common anti-inflammatory drugs such as aspirin and
ibuprofen have been assessed in animal models of stroke and have found only
minor success in reductions of behavioral deficits. Aspirin was used as an
antithrombotic agent for its antiplatelet properties. Aspirin administration resulted
in a 27% reduction of vascular death and infarction (Berger et al. 2004). Side
effects resulted in resistance to the drug and between 15% and 45% of the
patients in the studies were tolerant to the antiplatelet effects (Berger et al.
2004). Ibuprofen has been shown to inhibit cycloxygenase expression and
reduce the synthesis of prostaglandins from arachidonic acid in transient MCAO
(Cole et al. 1993). Animal models using permanent MCAO showed an increase
in infarction when treated with Ibuprofen suggesting that the beneficial effects of
this drug only work during reperfusion of transient MCAO, which showed a
decrease in infarction (Cole et al. 1993).
Cytokine inhibition has been examined as a potential treatment in an
attempt to reduce activation of inflammatory pathways and migration of
inflammatory cells during cerebral ischemia. Reduction of the expression of the
pro-inflammatory cytokine TNF-α and molecular inhibition of the adhesion
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molecule MCP-1 have shown promise in the decrease of neurological deficits
(Hughes et al. 2002; Nawashiro et al. 1997a; Nawashiro et al. 1997b). Again,
however, clinical and some animal trials of these agents have produced
unfavorable results. TNF-α, while inflammatory, also provides some
neuroprotection after stroke and inhibition of this cytokine can result in increased
damage (Barone and Feuerstein 1999). Reduction of the chemoattractant MCP1 results in accelerated atherogenesis, the increased formation of lipid deposits
on the inner walls of arteries. These deposits can eventually break free causing
embolic blockage of arteries leading to stroke (Fosslien 2005).

Novel Approaches for Treatment of Stroke
To develop a novel therapy for stroke, successes and failures must be
taken into account. While rtPA, neuroprotective agents, and anti-inflammatory
agents show some promise, individually these treatments do not result in a
feasible therapy of stroke that promotes neuroprotection, reduces infarct volume,
alleviates behavioral impairment and expands the therapeutic window of
administration. Recent research from the Pennypacker and Willing laboratories,
however, have shown that pharmacological treatments that combine both
neuroprotection and anti-inflammation greatly reduce infarction in the rat MCAO
stroke model which was first described by Longa et al. in 1989 (Longa et al.
1989). Human umbilical cord blood cell transfusion achieved these goals by
reducing infarction volume, decreasing motor deficits and showing protection at
delayed time points.
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Human Umbilical Cord Blood Cells
Recent studies have shown that human umbilical cord blood cells
(HUCBC) when used as a treatment for stroke, promote neuroprotection and
anti-inflammation to expand the therapeutic window of treatment up to 48 hours
after the initial insult (Newcomb et al. 2006; Vendrame et al. 2004). HUCBC are
a mononuclear fraction of cells containing hematopoietic stem cells that are
derived from the umbilical cord blood that is normally discarded after the neonate
is born. The mononuclear fraction consists of a heterogeneous population of
cells that can be distinguished from one another by cell surface antigens. Flow
cytometry analysis shows that monocytes and lymphocytes make up the majority
of the HUCBC mononuclear fraction, while the hematopoietic stem cells, bearing
the CD34 antigen, make up only 1% of the total fraction (Pranke et al. 2001).
The first beneficial effects of this treatment were shown when there was a
reduction in deficits of behavioral motor response in rats that received a
transfusion of HUCBC after MCAO (Chen et al. 2001). Further investigation of
the transfusion of HUCBC after MCAO showed that there was a 50 and 70%
reduction in infarction volume when administered 24 and 48 hours post MCAO,
respectively (Newcomb et al. 2006; Vendrame et al. 2004). Alternative
treatments that mimic the actions of HUCBC, such as sigma receptor activation,
were investigated to confirm that promoting both neuroprotection and antiinflammation result in the positive effects seen with cord blood cell therapy.
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Sigma Receptors
Activation of sigma receptors at delayed time points is a novel treatment
for stroke. Stimulation of these receptors promotes both neuroprotection and
anti-inflammatory effects in the CNS (Goyagi et al. 2001; Harukuni et al. 2000;
Harukuni et al. 1998; Su 1991). Sigma receptors were first discovered in 1976
by W. R. Martin but they were originally believed to be opioid receptors (Martin et
al. 1976). They are now known to be their own class of receptors with unique
structure and function. At this time an endogenous ligand for the sigma
receptors has not yet been determined. However, it has been postulated that
neurosteroids are these ligands. Sigma receptors can be divided into two distinct
classes based of pharmacological profile, sigma-1 and sigma-2 (Bowen et al.
1989).
Of the two receptors, more is known about sigma-1 since it has been
cloned (Hanner et al. 1996). While the three dimensional structure is still
unknown, it has been postulated to be a several transmembrane molecule.
From a protective perspective, sigma-1 receptor activation has been shown to be
neuroprotective by reducing glutamate toxicity in cultured neurons (Kume et al.
2002; Takahashi et al. 1996) and decreasing neuronal nitric oxide production in
rat transient MCAO (Goyagi et al. 2001; Lesage et al. 1995). Sigma-1 activation
can also result in an anti-inflammatory response by inhibiting inflammatory
cytokine production in macrophages and up-regulating the expression of IL-10,
an anti-inflammatory cytokine that can inhibit the endotoxin-induced production of
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proinflammatory cytokines (Bourrie et al. 1996; Bourrie et al. 1995; Bourrie et al.
2002; Derocq et al. 1995).
Much less is known regarding sigma-2. Although structure, cloning,
function and endogenous ligand have yet to be determined, it has been
discovered that sigma-2 has neuroprotective properties. Experiments have
shown that activation of this receptor modulates voltage-gated calcium and
sodium channels (Zhang and Cuevas 2002; Zhang and Cuevas 2005).
Modulation of these two channels at the time of stroke may result in inhibition of
excessive calcium influx into the neurons preventing necrotic and apoptotic
pathway activation.

1, 3-Di-o-tolyguanidine
To confirm the protective actions of HUCBC affecting stroke, a sigma
receptor ligand was selected based on the need to promote both neuroprotective
and anti-inflammatory effects. Therefore the sigma receptor ligand 1, 3-di-otolyguanidine (DTG), was picked for examination for its high affinity for both the
sigma-1 and sigma-2 binding sites (Quirion et al. 1992). We hypothesized that
activation of both the sigma-1 and sigma-2 receptors by this ligand would result
in increased neuroprotection and anti-inflammation at the site of injury.

Spleen
Another alternative target for the treatment of stroke is splenic reaction to
ischemic injury. Identification of HUCBC by human nuclei immunoreactivity and
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PCR analysis for human DNA showed that HUCBC localized to only the
hemisphere of the brain subjected to MCAO and to the spleen (Vendrame et al.
2004). These findings suggest that the spleen is involved in the overall stroke
mechanism that is affecting the body and HUCBC is potentially working through
the spleen to modulate immune cell responses to the brain.
The spleen is a secondary lymphoid organ whose functions are centered
on the peripheral circulation. It is located in the left hypochondriac region of the
abdominal cavity between the fundus of the stomach and the diaphragm. This
organ acts to remove old and damaged cells, filters the blood and initiates
immune responses to blood born antigens (Cesta 2006). The spleen is
comprised of two functionally and morphologically distinct compartments, the red
pulp and the white pulp. The red pulp filters blood to remove foreign material and
damaged erythrocytes. It is also a storage site for iron, erythrocytes, and
platelets. The functional charge of the white pulp is to initiate immune
responses, and store large amounts of the body’s lymphocytes and
macrophages (Balogh et al. 2004; Nolte et al. 2002). The spleen itself is
surrounded by a capsule composed of dense fibrous tissue, elastic fibers, and
smooth muscle (Cesta 2006).
Recent studies have reported that in animal models the spleen shrinks in
reaction to Parkinson’s and stroke injury to the brain (Benner et al. 2004; Offner
et al. 2006a; Offner et al. 2006b; Vendrame et al. 2006). These studies have
observed that shrinkage of the spleen is followed by a release of splenocytes into
the circulation. In the specific case of stroke, the spleen shrinks by 50% of its

28

weight. Treatment with HUCBC, besides reducing infarct volume, caused the
spleen to retain its size (Vendrame et al. 2006). This interaction with stroke
suggests that cerebral infarction relays a signal to the spleen, by soluble
chemicals or sympathetic innervation that results in a massive release of immune
response cells causing the organ to decrease in size. These released immune
cells can then infiltrate the brain via the disrupted blood brain barrier resulting in
enhancement of the peripheral immune response and the up-regulation of
inflammation at the site of insult. Determination of the exact interactions between
stroke and the spleen could produce a launching point for the development of
novel therapies for cerebral ischemia and is a focal point of the following
experiments.

The Current Study
The overall hypothesis of this work is that treatments that promote
neuroprotective and anti-inflammatory effects can modulate the
neurodegenerative deficits of ischemic injury. Evidence from the literature and
data from these experiments supports the theory that reduction of
neurodegeneration, modulation of immune inflammatory responses and the
contribution of peripheral inflammatory systems are effective targets for reducing
infarction expansion after stroke. The data presented a) shows universal sigma
receptor activation decreases neurodegenerative load of the infarction at a
delayed administration after stroke, b) the spleen contributes to stroke-induced
neurodegeneration, and c) autonomic innervation does not control splenic
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response to stroke. Here, it is proposed that simultaneous activation of
neuroprotective and anti-inflammatory effects by alternative targets of stroke
promote neuron survival. These treatments will also lead to reduced
inflammation by decreased activation or migration of peripheral immune cells
resulting in reduced infarction expansion, morbidity and mortality.
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Abstract
The only available treatment for embolic stroke is recombinant tissue
plasminogen activator, which must be administered within three hours of stroke
onset. We examined the effects of 1,3-di-o-tolyguanidine (DTG), a high affinity
sigma receptor agonist, as a potential treatment for decreasing infarct area at
delayed time points. Rats were subjected to permanent embolic middle cerebral
artery occlusion (MCAO) and allowed to recover before receiving subcutaneous
injections of 15 mg/kg of DTG at 24, 48, and 72 hours. At 96 hours the rats were
euthanized, and brains harvested and sectioned. Infarct areas were quantified at
the level of the cortical/striatal and cortical/hippocampal regions in control
(MCAO-only) and DTG treated animals using the marker for neurodegeneration,
Fluoro–Jade. DTG treatment significantly reduced infarct area in both
cortical/striatal and cortical/hippocampal regions by >80%, relative to control rats.
These findings were confirmed by immunohistochemical experiments using a
neuronal marker, mouse anti-neuronal nuclei monoclonal antibody (NeuN), which
showed that application of DTG significantly increased the number of viable
neurons in these regions. Furthermore, DTG blocked the inflammatory response
evoked by MCAO, as indicated by decreases in the number of reactive
astrocytes and activated microglia/macrophages detected by immunostaining for
glial fibrillary acidic protein (GFAP) and binding of isolectin IB4, respectively.
Thus, our results demonstrate that the sigma receptor-selective agonist, DTG,
can enhance neuronal survival when administered 24 hr after an ischemic stroke.
In addition, the efficacy of sigma receptors for stroke treatment at delayed time
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points is likely the result of combined neuroprotective and anti-inflammatory
properties of these receptors.

Key words:
Stroke♦Sigma receptors♦Neuroprotection♦Anti-inflammation♦Middle Cerebral
Artery Occlusion♦Fluoro-Jade♦Infarction♦Ischemia
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Introduction
Stroke is the leading cause of severe disability and the third leading cause
of death in the United States of America (AHA, 2005). Intravenous application of
recombinant tissue plasminogen activator (tPA), a thrombolytic agent, is the only
FDA approved treatment for stroke and has a very limited therapeutic time
window (1995). This “clot-buster” must be administered within three hours of
stroke onset (Albers et al. 2004), and can produce possible adverse effects such
as hemorrhage and reperfusion damage from oxygen free radicals (Hacke et al.
1999; Kumura et al. 1996; Peters et al. 1998). The limitations and adverse
effects of tPA have stimulated the search for alternative treatments for stroke.
When a cerebral embolic stroke occurs, a thrombus blocks blood
perfusion to the brain and triggers a series of events that ultimately result in
neuronal death. The disruption in blood supply directly results in the cessation of
oxygen and nutrient delivery, which metabolically compromises the neurons and
produces an infarction. The infarct zone contains two regions associated with
ischemic cell death. The center of the infarction or “core” is the area directly
affected by the decrease in blood perfusion, and is where the greatest
concentration of cell death can be found. Surrounding the core is the penumbra,
a region with diminished blood flow but where collaterals provide some oxygen
and nutrients. However, perfusion in the penumbra is sufficiently reduced that
physiological function is arrested and some degeneration of neurons occurs
(Ginsberg 2003).
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Neuronal death is enhanced by secondary inflammation caused by the
immune response in the penumbra. The inflammatory response is primarily from
resident activated microglia and infiltrating macrophages, which enter the central
nervous system through the degrading blood brain barrier (Stoll et al. 1998).
Reactive astrocytes and microglia exacerbate cerebral inflammation via their
production of pro-inflammatory cytokines and chemokines (Trendelenburg and
Dirnagl 2005). These immune cells, which normally protect the brain via
destruction of pathogens and promotion of tissue repair, become overactivated,
and further promote the expansion of tissue damage by releasing high levels of
nitric oxide (NO), glutamate, tumor necrosis factor-α (TNF-α), and interleukin-1
(IL-1)(Bal-Price and Brown 2001; Heales et al. 1999; Hertz et al. 2001).
It is our hypothesis that therapeutic interventions that provide
neuroprotection and reduce inflammation will decrease damage to the penumbra,
which will reduce the extent of the damage produced by stroke. Our hypothesis
is based on recent studies which have shown that transfusion with human
umbilical cord blood cells (HUCBC), which possess both of these properties,
results in both infarct volume reduction and expansion of the therapeutic window
(Newcomb et al. 2005; Vendrame M et al. 2005; Vendrame et al. 2004).
Activation of sigma receptors has been shown to decrease neuronal death
associated with hypoxia and to elicit an anti-inflammatory response(Bourrie et al.
2002; Goyagi et al. 2001). Thus, activation of sigma receptors may mimic the
effects of HUCBC following stroke and provide for the expansion of the
therapeutic time window for treatment after such injury.

58

Two distinct subtypes of sigma receptors have been identified on the basis
of their pharmacological profile (Bowen et al. 1989; Quirion et al. 1992). Thus
far, only the sigma-1 receptor has been cloned (Hanner et al. 1996), but the
sigma-2 receptor has been shown to be a separate molecular entity (Langa et al.
2003). Sigma-1 receptor activation has been shown to prevent neuronal death
associated with glutamate toxicity in cultured neurons (Kume et al. 2002;
Takahashi et al. 1996) and to diminish infarct damage by decreasing neuronal
nitric oxide production in vivo (Goyagi et al. 2001; Lesage et al. 1995). Sigma-1
also modulates the immune response by inhibiting TNF-α production in
endotoxin-activated macrophages and acts as an anti-inflammatory agent by
stimulating the expression of interleukin-10 during in vivo and in vitro ischemic
simulations (Bourrie et al. 1996; Bourrie et al. 1995; Bourrie et al. 2002; Derocq
et al. 1995). In contrast, less is known about sigma-2 receptors. However these
receptors have been shown to regulate voltage-activated calcium and sodium
channels in neurons (Zhang and Cuevas 2002; Zhang and Cuevas 2005), which
is likely to enhance neuronal survival following stroke (Tanaka et al. 2002).
The ability of sigma-1 and sigma-2 receptors to target different ion
channels and different processes likely involved in neuronal demise following
ischemia suggests that both should be targeted for stroke therapy. 1,3-di-otolyguanidine (DTG), the sigma ligand used here, has a high affinity for both
sigma 1 and 2 receptors (Quirion et al. 1992). We believe that activation of both
sigma receptors will result in additive or synergistic neuroprotective and antiinflammatory effects. In this study, we administered DTG subcutaneously to rats
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starting at 24 hours after permanent embolic middle cerebral artery occlusion
(MCAO) and found that this treatment results in a significant decrease in
infarction area.
Materials and Methods
Animals - Fifty eight adult male Sprague-Dawley rats (Harlan, Indianapolis, IN)
weighing 300 to 350 g were housed in a climate controlled room with water and
laboratory chow available ad libidum. Animals were cared for according to the
guidelines of the IACUC of the University of South Florida’s College of Medicine.

Permanent Middle Cerebral Artery Occlusion - MCAO surgery was performed
as previously reported by Vendrame et al (Vendrame et al. 2004) and originally
described by Longa et al (Longa et al. 1989). Laser Doppler Radar (LDR) was
used to monitor decrease in blood perfusion which indicates successful occlusion
(Moor Instruments Ltd, Devon, England). A 2 mm diameter hole was drilled into
the right parietal bone (1 mm posterior and 4 mm lateral from bregma), and a
guide screw was set. The LDR probe (MP10M200ST; Moor) was inserted into
the guide screw, and the tip of the probe was placed against the pial surface of
the brain. Rats that did not show >55% reduction in perfusion during MCAO
were excluded from the study because they generally failed to exhibit infarct
damage. For MCAO, the embolus (4cm long, 6lb test monofilament) was
advanced up the internal carotid artery into the middle cerebral artery and tied off
at the internal/external carotid junction to produce permanent occlusion. The rat
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was then sutured, given a 1 ml subcutaneous injection of saline, and allowed to
wake in a fresh cage.

Treatments and Tissue Preparation - Rats were randomly assigned to 1 of 7
groups: (1) MCAO (n=7); (2) MCAO and 15 mg/kg DTG in a 3% lactic acid
vehicle (n=11); (3) MCAO and 30 mg/kg DTG (n=16); (4) MCAO and bi-daily
injections of 30 mg/kg DTG (n=12); (5) MCAO and 10 mg/kg N-[2-(3,4dichlorophenyl) ethyl]-N-methyl-2-(dimethylamino) ethylamine (BD 1047) (n=4);
(6) MCAO and 10 mg/kg BD1047 + 30 mg/kg DTG (n=4); (7) sham/MCAO and
15 mg/kg DTG (n= 4). DTG and BD1047 were obtained from Sigma Chemical
Co (St. Louis, MO) and Tocris (Ellisville, Missouri), respectively. Injections were
administered 24, 48, and 72 hours post MCAO. All rats received daily injections
of 0.04 ml of ketophen and 1 ml of saline. The animals were sacrificed at 96
hours, and perfused with saline and 4% paraformaldehyde. The brains were
harvested, fixed in paraformaldehyde, immersed in serial solutions of 20% and
30% sucrose, and sliced into 30µm sections. Sections were either cold mounted
on slides or placed in Walter’s Anti-freeze cryopreservative.

Fluoro-Jade Histochemistry - Coronal brain sections from 1.7 to -3.3 mm from
bregma containing cortical, striatal and hippocampal regions were stained with
Fluoro-Jade. Fluoro-Jade labels degenerating neurons, and is more sensitive
than triphenyltetrazolium chloride (TTC) for identifying neurodegeneration
(Duckworth et al. 2005). This method was adapted from that originally described
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by Schmued et al (Schmued et al. 1997) and has been detailed previously by
Duckworth et.al (Duckworth et al. 2005). Tissue was cold mounted, thawed, and
dried onto glass slides. Slides were sequentially placed in 100% ethanol for 3
min, and 70% ethanol and deionized water for 1 min each. Sections were then
oxidized using 0.06% KMnO4 solution for 15 min followed by three rinses for 1
minute each in PBS. Sections were stained in a 0.001% solution of Fluoro-Jade
(Histochem, Jefferson, AR) in 0.1% acetic acid for 30 min. Slides were rinsed
with PBS, allowed to dry at 45 oC for 20 min, cleared with xylene, and cover
slipped were affixed to slides with DPX medium (Electron Microscopy Sciences,
Ft. Washington, PA).

Immunohistochemistry and Histochemistry - Immunohistochemistry was
performed as previously detailed by Butler et al (Butler et al. 2002). Free floating
brain sections were pre-incubated in permeabilization buffer, 0.3% lysine, 0.3%
TritonX-100, and 2% goat serum in phosphate buffered saline (PBS) for 1 hour.
Sections were washed three times with PBS between each incubation step. The
tissue was then incubated in primary antibody solution overnight either with
mouse anti-glial fibrillary acidic protein monoclonal antibody (GFAP) at a
1:10,000 dilution (MAB3402, Chemicon, Temecula, CA) or mouse anti-neuronal
nuclei monoclonal antibody (NeuN) at a 1:30,000 dilution (Chemicon, Temecula,
CA). Sections exposed to antibodies directed against these proteins were
subsequently incubated for 1 hour in biotinylated horse anti-mouse secondary
antibody solution (Vector Laboratories, Burlingame, CA) followed by avidin /
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biotin / horseradish peroxidase complex (VectastainElite ABC kit; Vector) for 1 h.
Sections were then washed 3x in PBS, and metal-enhanced 3, 3’diaminobenzidine (Pierce, Rockford, IL) was used for color development. For
experiments involving Griffonia simplicifolia Isolectin (IB4/Alexa Fluor 488;
Molecular Probes Eugene, Oregon), sections were incubated overnight in
isolectin IB4 (5µg/ml). All sections were mounted on slides, dried, cleared
sequentially with 100%, 95%, and 70% ethanol and xylene, and coverslips
affixed with DPX.

Infarct Area and Immunohistochemistry Quantification - Images of FluoroJade stained brain sections, 5 per cortical/striatal and 4 per cortical/hippocampal
regions for each rat from 1.7 to -3.3 mm from bregma, were acquired with the
Olympus IX71 microscope controlled by DP manager software (Olympus
America Inc, Melville, NY) at a magnification of 12.5x. All other images were
taken with a Zeiss Axicam Color (model 412-312) camera and Zeiss Axioscope 2
(model 801572) microscope controlled by Openlab software (Improvision Ltd,
Lexington MA). Images were edited with Jasc Paintshop Pro to sharpen and
enhance contrast of the images to the same specifications. Image analysis was
performed utilizing NIH Image J software to determine the area of
neurodegeneration by particle analysis in the regions of interest. The area of the
contralateral side of the brain tissue was measured and used to compensate for
possible edema in ipsilateral hemispheres. NeuN immunostaining was analyzed
using the NIH Image J software to count NeuN positive cells by particle analysis
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in the ipsilateral hemispheres of the cortical/striatal and cortical/hippocampal
regions of the rat brains at a maginification of 10X.

Statistical Analysis - Data were analyzed using SigmaPlot 2000 (SPSS
Science, Chicago, IL). Data points represent means ± standard error of the
mean (SEM). Multiple group comparisons were conducted using a One-Way or
a Two-Way ANOVA, as appropriate, followed by post-hoc analysis with a Tukey
or Dunn’s Test to identify differences between individual groups. Differences
were considered significant if p< 0.05. Survival rates were analyzed using a
Kaplan-Meier Survival Analysis and post-hoc with a Holm-Sidak test for pairwise
multiple comparison.

Results
DTG Dose Quantification
Reports in the literature indicate that doses of DTG as high as 30 mg/kg
are well tolerated by rats (Rawls et al. 2002). Thus, this high dose of DTG was
used to determine if stimulation of sigma receptors was neuroprotective at
delayed time points. Furthermore, to confirm that the effects of DTG were
mediated by activation of sigma receptors, the sigma receptor selective
antagonist, BD1047, was used at concentrations (10 mg/kg) previously shown to
abolish systemic effects of DTG (Rawls et al. 2002). Rats received
subcutaneous injections of DTG at 30 mg/kg daily, 15 mg/kg daily, 30 mg/kg bidaily, 10 mg/kg daily BD1047, or BD1047 (10 mg/kg) + DTG (30 mg/kg)
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administered at 24, 48 and 72 hours post surgery with animals being sacrificed at
96 hours. The percent survival was defined as the number of rats that survived
96 hours post MCAO divided by the total number of rats that awoke from
anesthesia. The MCAO and 15 mg/kg DTG daily groups produced survival rates
of over 70%, while 30 mg/kg DTG daily had a survival rate under 40% Fig. (1). In
contrast, the survival rates of BD1047 alone, BD 1047 + DTG, and 30 mg/kg bidaily were ≤25%, indicating that high concentrations of DTG and inhibition of
sigma receptors worsen survival outcomes. Given that none of the sham
animals died following DTG application, high concentrations of DTG are not
lethal in the absence of MCAO Fig. (1). The dose of 15 mg/kg per day did not
enhance mortality relative to the MCAO only group, and therefore was the dose
chosen for the subsequent study.

DTG Treatment 24-hr post-MCAO Decreases Infarct Size
The marker for neurodegeneration, Fluoro-Jade, was used to determine infarct
area after MCAO. Figure 2 shows representative photomicrographs of coronal
sections from cortical/striatal (Figure 2a and 2c) and cortical/hippocampal (Figure
2b and 2d) regions obtained form rats in the absence and presence of DTG
treatment post-MCAO. Fluoro-Jade staining was observed in brain sections from
all animals that underwent MCAO, but absent from sections collected from sham
controls. While Fluoro-Jade staining was observed in DTG treated (15 mg/kg)
animals (Fig 2c and 2d), this was less pronounced than in MCAO only rats (
Figure 2a and 2b). Analysis of similar sections obtained from the individual
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groups showed that Fluoro-Jade labeled 44 ± 5% and 29 ± 3% of the
cortical/striatal and cortical/hippocampal regions, respectively, in MCAO-only
rats. However, in DTG-treated animals (n=7) infarct areas were 6±4% and 2±2%
in the cortical/striatal and cortical/hippocampal regions, respectively Fig. (3).
This decrease in infarct area was statistically significant (p < 0.001), and
demonstrates that DTG application at delayed time points can effectively
decrease stroke-induced neurodegeneration.

DTG-induced Enhancement of Neurosurvival
To confirm that DTG increase the number of neurons surviving MCAO in rats, we
immunostained for the neuron-specific protein, NeuN, to selectively label the
nuclei of viable cells. Figure 4 shows representative brain sections from DTG
treated and untreated rats immunostained for NeuN. Whereas NeuN expression
was absent from the infarct zone of MCAO-only rats ( Figure 4a-c), NeuN
staining was readily visible in the infarct zone of animals injected with DTG
(Figure 4d-f). In identical experiments, the total number of NeuN-positive
neurons were counted by image analysis, and average number per visual field
determined. These values are shown in Figure 5, and demonstrate that MCAO
significantly decreases the number of viable neurons in the ipsilateral
cortical/striatal and cortical/hippocampal infarct zones, relative to the respective
regions in the contralateral hemisphere. Injection with DTG significantly
increased the number of viable neurons in both ipsilateral cortical/striatal and
cortical/hippocampal infarct zones (p < 0.001). Furthermore, the number of
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neurons detected in these areas of the ipsilateral hemisphere were comparable
to those observed in equivalent areas of the contralateral side (Figure 5). Thus,
DTG increases neuronal survival to the extent that the number of surviving cells
was not statistically different from that observed in sham controls (Figure 5).

DTG Treatment Decreases Expression of Inflammatory Markers
Experiments in our laboratory have shown that reduced brain inflammation
is a key component to treating stroke at delayed time points (Newcomb et al.
2005; Vendrame M et al. 2005). Thus, to ascertain if stimulation of sigma
receptors by DTG exerts an anti-inflammatory response, we examined
inflammatory markers for both astrocytes and microglia in brain sections from the
experiments discussed above. Reactive astrocytes, which participate in the
inflammatory response in the brain following injury (O'Callaghan 1994), exhibit
high levels of the distinguishing marker, GFAP. Thus, GFAP immunoreactivity
was used to label reactive astrocytes responding to the ischemic injury produced
by our model. Representative images showing GFAP labeling in tissue sections
collected from MCAO-only and DTG treated animals are shown in Figure 6.
Astrocytes containing high levels of GFAP were always observed in MCAO-only
animals, and these astrocytes were primarily located in the areas surrounding the
infarction Figure 6a-c). However, the area inside of the infarction was noticeably
devoid of astrocytes expressing GFAP in these sections. In animals receiving
DTG, brain sections exhibited a marked decrease in the level of GFAP
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expression. Moreover, astrocytes with this low level GFAP-labeling were
detected throughout the infarct zone Figure 6d-f).
Inflammatory response of the central nervous system also involves
activation of microglia and infiltration of systemic macrophages. Both of these
cells express the surface protein IB4 when activated in response to injury, and
can be selectively labeled in this state using isolectin IB4 (Goldstein and Winter
1999). Figure 7 shows representative photomicrographs of tissue sections of
cortical/striatal and cortical/hippocampal regions labeled with isolectin IB4 from
animals subjected to MCAO with and without DTG treatment. MCAO evokes a
pronounced increase in isolectin IB4 labeled cells in the infarct zone of untreated
animals (Figure 7a and 7b). However, MCAO fails to elicit these elevations in
isolectin IB4-positive cells in the infarct zone of sections taken from animals
treated with DTG (Figure 7c and 7d). Isolectin IB4 labeling was also absent from
sections taken from sham control animals (Figure 7e and 7f). Taken together,
our data suggest that application of DTG blunts the inflammatory response of the
brain following MCAO. This depression of neuroinflammation is likely to
contribute to the enhanced neuronal survival reported here.
Discussion
The major finding reported here is that the application of DTG 24 hr after
stroke injury significantly decreases neurodegeneration in rats subjected to
MCAO. Moreover, it was observed that the administration of this sigma ligand
depresses the inflammatory response evoked by the ischemic insult. The role of
sigma receptors in the effects of DTG were supported by the observation that the
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sigma-selective antagonist, BD-1047, worsened stroke outcomes. Thus, our
data support the hypothesis that the window for treatment of stroke extends
beyond the limitations of the currently available therapy, and that sigma receptors
are a viable target for stroke therapy at delayed time points.
Two lines of evidence presented here confirm that DTG is neuroprotective
when administered 24 hr post stroke. First, DTG significantly decreased FluoroJade staining, which is consistent with reduced neurodegeneration, by >85%
relative to untreated MCAO animals. Second, the number of surviving cells
detected in the infarct zone with the neuron specific marker, NeuN, was
increased by >83% in DTG treated animals relative to MCAO-only animals.
Moreover, the number of viable cells observed in the ischemic region of DTG
treated animals was similar to the number of cells present in equivalent regions
of sham controls. Previous studies on the neuroprotective properties of sigma
receptor activation following MCAO have focused on a transient ischemia model
(1-2 hr occlusion) and have commenced intravenous application of sigma-1
selective ligands, such as 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP), 1-2 hr
following reperfusion (Takahashi et al. 1996). Brain sections taken from animals
treated with PPBP showed ~40% decrease in neurodegeneration (Takahashi et
al. 1996). Unlike observations reported here, some studies suggest that acute
application of PPBP following MCAO fails to decrease infarct injury in the
striatum of rats (Harukuni et al. 2000). The sigma-1 ligand, JO 1784, has also
been shown to be effective for decreasing brain injury following global ischemia
when applied ≥ 1 hr following the ischemic insult (O'Neill et al. 1995). Our
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studies, however, indicate that DTG can exert its neuroprotective properties even
when treatment begins 24 hr post-stroke.
The dose of DTG used here to diminish stoke injury without compromising
survival rates (15 mg/kg) is comparable to doses previously used of this sigma
ligand to elicit sigma receptor-mediated effects in vivo, such as hypothermia (130 mg/kg) and antinociception (10-20 mg/kg) (Kest et al. 1995; Rawls et al.
2002). The mechanism(s) by which higher concentrations of DTG (30 mg/kg)
increase mortality following MCAO remains to be determined. However, sigma
receptors have been shown to modulate cardiac function directly by acting on
cardiac muscle and to regulate neurons that mediate autonomic control of the
heart (Novakova et al. 1998; Zhang and Cuevas 2002; Zhang and Cuevas 2005).
Given the fact that cardiovascular abnormalities, including cardiac arrhythmias,
are associated with stroke (Klingelhofer and Sander 1997), high concentrations
of DTG may exert their deleterious effects via enhancing cardiac dysfunction
following stroke injury.
The inflammatory response that occurs in the central nervous system
following injury, such as that produced by ischemic stroke, plays a significant role
in enhancing neurodegeneration. The sequence of events leading to cerebral
inflammation after acute focal ischemia begins with the rapid activation of
microglia within 24 hours of the insult (Schroeter et al. 1997). This event is
followed by systemic macrophage infiltration through the compromised blood
brain barrier at 48 hours post-stroke (Schroeter et al. 1997). Subsequently,
reactive astrocytes begin to release glutamate, nitric oxide, TNF-α, and other
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factors, which result in increased inflammation contributing to delayed neuronal
death (Swanson et al. 2004). Based on data presented here, DTG blunts the
glia-mediated inflammatory response evoked by MCAO. Three mechanisms
may account for the observed sigma receptor-mediated anti-inflammatory
response. First, direct neuroprotection by DTG administration may result in
reduced production and release of signaling molecules which trigger the proinflammatory response. Various in vitro studies have shown that stimulation of
sigma receptors decreases neuronal death in response to hypoxia and glutamate
excitotoxicity (DeCoster et al. 1995; Lockhart et al. 1995). Second, stimulation of
sigma receptors on cells involved in inflammation in the CNS may dampen this
response. Sigma receptor agonists like SSR125329A and SR 31747 decrease
inflammation by inducing the release of anti-inflammatory cytokines such as
interleukin-10 and by decreasing the release of pro-inflammatory cytokines such
as TNF-α (Bourrie et al. 2002) (Derocq et al. 1995). Results from our laboratory
have show that DTG treatment inhibits the production of nitric oxide and TNF-α
from cultured microglia in response to lipopolysaccharide (Hall et al. 2005),
suggesting that DTG could directly inhibit the inflammation associated with
ischemic injury in our in vivo model of stroke. Finally, the anti-inflammatory
effects of DTG may involve a combination of both decreased signaling due to
neuroprotection and an arrest of the endogenous inflammatory response.
Regardless of the mechanisms involved, the anti-inflammatory effects of sigma
receptor stimulation is in part responsible for the DTG-evoked depression of
delayed neuronal death induced by ischemia.
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Few treatments have shown success in expanding the therapeutic window
for stroke. One approach that has exhibited promise in treating stroke at delayed
time points is intravenous infusion of HUCBC. HUCBC have been shown to
effectively decrease infarct volume by 50-80% when injected 24-48 hr in rats
following MCAO (Newcomb et al. 2005; Vendrame M et al. 2005; Vendrame et
al. 2004). Like DTG, HUCBC treatment shows both neuroprotective and antiinflammatory properties. This observation is consistent with our hypothesis that
both of these properties are essential for effective treatment of stroke at delayed
time points. Moreover, HUCBC are potentially activating sigma receptors upon
transfusion through release of neurosteroids. Umbilical plasma has been shown
to contain more than double the concentration of neuroactive steroids when
compared to adult plasma (Hill et al. 2000). Neurosteroids have been shown to
have high affinity for sigma receptors and have been proposed as the
endogenous ligand for these receptors (Maurice 2004).
The specific sigma receptor subtype mediating the neuroprotective effects
of DTG remains to be identified. However, data collected in our laboratory and
by other investigators suggests that both sigma-1 and sigma-2 receptors are
likely to be involved in the enhanced neurosurvival reported here. Sigma-1
receptors have been shown to block both voltage-gated K+ channels and NMDA
receptors (Aydar et al. 2002; Zhang and Cuevas 2005);(Nuwayhid and Werling
2003). Both of these ion channel types have been linked to the neuronal
damage which is produced by ischemic stoke (Bonde et al. 2005; Gido et al.
1997). Our laboratory has now shown that sigma-1 receptors can decrease
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calcium elevations elicited by ischemia in neurons in vitro (Zhang and Cuevas
2005), which would also provide neuroprotection (Mattson et al. 2000). Sigma-2
receptors have been shown to inhibit voltage-gated Ca2+ channels (Zhang and
Cuevas 2002), and the inhibition of these channels is neuroprotective (Kristian
and Siesjo 1997). In addition to regulating ion channels, sigma receptors are
likely to modulate other processes that contribute to neuronal injury following
stoke. Sigma-1 and sigma-2 receptors have been detected in lipid rafts in
various cell types, and are likely to modulate cytokine signaling involving these
microdomains (Hayashi and Su 2005). Both sigma receptor subtypes have also
been implicated in the regulation of apoptosis in tumor cell lines, with sigma-1
receptors inhibiting apoptosis and sigma-2 receptor promoting apoptosis in these
cells (Crawford and Bowen 2002; Spruce et al. 2004). However, the role of
sigma receptors in regulation of cell survival in native non-tumor cells remains to
be established.
In conclusion, our results clearly demonstrate that the sigma receptorselective agonist, DTG, can enhance neuronal survival when administered 24 hr
after an ischemic stroke. Conversely, application of the sigma receptor
antagonist, BD-1047, decreases survival rates following MCAO. Thus, our
studies identify sigma receptors as one of the first potential targets for expanding
the therapeutic window beyond that provided by the currently available
pharmacological treatments. In addition, the efficacy of sigma receptors for
stroke treatment at delayed time points is likely the result of combined
neuroprotective and anti-inflammatory properties of these receptors.
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Figure 1: Effects of sigma receptor ligands on MCAO survival rates.
Survival rate of sham control injected with 15mg/kg of DTG (Sham + DTG 15),
and MCAO rats under the indicated conditions. Rats subjected to MCAO
received vehicle alone (No Drug), DTG at 15 mg/kg or 30 mg/kg (DTG 15 QD,
DTG 30 QD, DTG 30 BID), 10 mg/kg BD 1047 (BD 1047 10 QD), or 10 mg/kg BD
1047 and 30 mg/kg DTG (BD 1047 + DTG 30 QD). QD and BID denote once
daily or twice daily administration of the compounds, respectively. Asterisks
indicate significant difference from DTG 30 BID. All injections commenced at 24
hr and continued to 72 hr post surgery.
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Figure 2: DTG treatment reduced Fluoro-Jade staining when administered
24 hours post-MCAO. Photomicrographs of brain sections were taken from
MCAO rats in the absence (MCAO; panels A and B) and presence of DTG
treatment (MCAO + DTG 15 mg/kg; panels C and D). Coronal sections were
collected at the level of the cortical/striatal (Striatum; panels A and C) or
cortical/hippocampal (Hippocampus; panels B and D) regions. Fluoro-Jade
staining appears as bright green coloration and is indicative of area damaged by
the ischemic insult. Scale bars represent 5mm at a magnification of 12.5X.
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• Relative infarct area – to compensate for edema – ipsilateral FJ
area/contralateral hemisphere area
• * p<0.001
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Figure 3: Quantification of DTG-elicited reduction in post-MCAO FluoroJade staining. Fluoro-Jade staining was analyzed in the cortical/striatal
(Striatum, black bars) and cortical/hippocampal (Hippocampus, gray bars)
regions of sham controls (Sham), rats subjected to MCAO receiving only vehicle
(MCAO) and rats subjected to MCAO receiving 15 mg/kg DTG 24 hours postsurgery (DTG). Bars represent mean ± standard error. Asterisks denote
significant difference from respective areas of sham control and DTG treated
rats, and was determined using a two way ANOVA followed by post hoc analysis
with a Dunn’s Test for multiple group comparison (p<0.01).
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Figure 4: DTG treatment increases NeuN immunostaining when
administered 24 hours post-MCAO. Photomicrographs of brain sections were
taken from MCAO rats in the absence (MCAO; panels A-C) and presence of
DTG treatment (MCAO + DTG 15 mg/kg; panels D-F). Coronal sections were
collected at the level of the ipsilateral cortical/striatal (Striatum; panels A, C, D
and F) or cortical/hippocampal (Hippocampus; panels B and D) regions. Boxes
in panels A and D indicate field of view shown at higher magnification in panels C
and F, respectively. Individually stained nuclei from neurons of the
cortical/striatal regions were visualized using higher magnification (200X; panels
C and F). NeuN staining appears as dark brown coloration and is indicative of
viable neurons. Scale bars (A, B, D, and E) represent 30µm at a magnification of
40X. Scale bars for C and F represent 50µm at 200X.
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Figure 5: DTG treatment at delayed time points significantly increases the
number of NeuN positive cells following MCAO. The number of NeuN
positive neurons detected in ipsilateral (IPSI) and contralateral (CONTRA)
hemispheres of cortical/hippocampal (Hippocampus) and cortical/striatal
(Striatum) regions of sham control rats (SHAM, white bars), MCAO rats injected
with vehicle alone (MCAO, black bars) and MCAO rats treated with 15 mg/kg of
DTG (DTG, gray bars). Bars represent mean count ± standard error. Statistical
significance from equivalent region in the contralateral hemisphere is indicated
by the asterisks, and from the ipsilateral hemisphere of SHAM and DTG groups
by the pound symbol (p<0.01 for both). Statistical significance was determined
using a two way ANOVA followed by post hoc analysis with a Tukey Test for
multiple group comparison.
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Figure 6: DTG decreases the intensity of GFAP immunostaining
surrounding the infarct zone when administered 24 hours post-MCAO.
Photomicrographs of brain sections were taken from MCAO rats in the absence
(MCAO; panels A-C) and presence of DTG treatment (MCAO + DTG 15 mg/kg;
panels D-F). Coronal sections were collected at the level of the ipsilateral
cortical/striatal (Striatum; panels A, C, D and F) or cortical/hippocampal
(Hippocampus; panels B and D) regions. Boxes in panels A and D indicate field
of view shown at higher magnification in panels C and F, respectively. Reactive
astrocytes showing high levels of GFAP were observed in the cortical/striatal
region using higher magnification (200X; panels C and F). GFAP staining
appears as dark brown coloration. Scale bars in panels A, B, D and E represent
30µm at a magnification of 40X, and in panels C and F represent 50µm at 200X.
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Figure 7: DTG treatment decreases Isolectin IB4 binding when
administered 24 hours post-MCAO. Photomicrographs of coronal brain
sections were taken from the ipsilateral cortical/striatal region of MCAO rats in
the absence (MCAO; panels A and B) and presence of DTG (15 mg/kg)
treatment (MCAO + DTG; panels C and D) as well as sham controls treated with
DTG (SHAM; panels E and F). Boxes in panels A, C and E indicate field of view
shown at higher magnification in panels B, D and F, respectively. Individual
labeled activated microglia and/or macrophages from cortical/striatal regions
were visualized using higher magnification (200X; panels B, D and F). Isolectin
IB4 labeling appears as bright green coloration. Scale bars (A, C, E) represent
20µm at 40X, and scale bars (B, D, F) represent 50µm at 200X.
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Abstract
Stroke, a cerebrovascular injury, is the first cause of disability and third cause of
death in the world (W.H.O. 2007). Recent reports implicate that antiinflammation enhances neurosurvival to limit expansion of the infarction. The
immune response that initiates from the spleen has been linked to the systemic
inflammatory response to stroke, contributing to neurodegeneration. Here we
show that removal of the spleen significantly reduces neurodegeneration after
ischemic insult. Rats splenectomized two weeks prior to permanent middle
cerebral artery occlusion had a >80% decrease in infarction volume in the brain
compared to those rats that were subjected to the stroke surgery alone.
Splenectomy also resulted in decreased activated microglia, macrophages, and
neutrophils present in the brain tissue. Our results demonstrate that the
peripheral immune response as mediated by the spleen is a major contributor to
the inflammation that enhances neurodegeneration occurring in the brain after
stroke.
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Introduction
Protecting neurons and blunting the inflammatory response are key components
for developing new treatments to alleviate the cerebral damage, disability and
ultimately death caused by stroke. Currently the only FDA approved treatment
for stroke is tissue plasminogen activator (tPA), a clot buster that has a limited
three hour therapeutic window of administration after stroke leaving only a 33%
success rate (Marler and Goldstein 2003). This treatment has no
neuroprotective or anti-inflammatory properties making it unsuitable for treating
those key components of stroke that result in expanding ischemic damage.
Therefore it is necessary to develop new therapies for this injury with a complete
understanding of the mechanism of interaction between the body’s immune
response to the ischemic injury as well as the neurodegeneration that is
occurring in the brain.
After the initial ischemic injury, a compromised blood brain barrier and
expression of adhesion molecules by the vascular endothelial cells permit an
influx of peripheral immune cells including macrophages, neutrophils, leukocytes,
T cells and B cells (Emsley et al. 2003). This peripheral immune reaction to the
brain ischemia exacerbates the local brain inflammatory response leading to
enhanced neurodegeneration. Previous studies have demonstrated altered
splenic function after a stroke and increased circulating proinflammatory
cytokines (Offner et al. 2006b; Vendrame et al. 2006). These infiltrating cells and
increased pro-inflammatory cytokines may negatively impact stroke outcome
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(Lucas et al. 2006). Therefore a potential target for new stroke therapies to
decrease stroke-induced inflammation may be the peripheral immune system.
Animal models of brain injury like 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP)(Benner et al. 2004), and transient (Offner et al.
2006b) or permanent middle cerebral artery occlusion (MCAO) (Vendrame et al.
2006) report that there is a reduction in the spleen weight, which may result from
the release of splenocytes. Transfusion of human umbilical cord blood cells
(HUCBC) 24 hours after permanent MCAO in rats results in retention of the
spleen’s mass as well as a reduction of infarct size by 60% (Vendrame et al.
2006). Further, there was an increase in the anti-inflammatory cytokine,
interleukin-10, with this treatment. These results are consistent with the
hypothesis that the spleen responds to the injury in the brain by releasing stored
immune cells into the bloodstream which infiltrate the brain and promote a
secondary inflammatory response to enhance neurodegeneration. By examining
the effects of splenectomy in the in vivo MCAO stroke model, we now show that
the spleen greatly contributes to the peripheral immune cells that invade the CNS
at the time of ischemic injury. Furthermore, our findings imply that the spleen will
be a starting point in development of novel therapies that target the splenic
immune response after stroke, and ultimately produce a treatment that can target
stroke at an extended therapeutic window.

100

Materials and Methods
Animals - Male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 300 to
350 g were housed in a climate controlled room with water and laboratory chow
available ad libidum. Animals were cared for according to the guidelines of the
IACUC of the University of South Florida’s College of Medicine.

Splenectomy – Male Sprague-Dawley rats weighing 300 to 350 g were
anesthetized and maintained with 3 to 4% isofluorane in 100% oxygen.
Splenectomy was performed by making a 2 cm dorsal midline skin incision in the
rat at the caudal terminus at the level of the 13th rib. Opening the abdominal wall
on the anatomical left, 1.5 to 2.5 cm from midline exposed the spleen. With blunt
forceps, the organ, (with accompanying blood vessels and pancreatic tissue),
was exteriorized through the incision. The blood vessels were ligated; the spleen
was removed and stored at -80°C. The skin incision was closed with 3-0 sutures.

Laser Doppler Radar Blood Flow Measurement – Rats were anesthetized and
maintained with 3 to 4% isofluorane in 100% oxygen, The rat’s head and neck
were shaved. Using a scalpel, an incision was made to expose the plates of the
skull on the side that was ipsilateral to the MCAO. Once the incision was made,
the skin was spread open and the membrane covering the skull pushed aside by
rubbing with a cotton tipped applicator. Using a microdrill a small hole was drilled
through the skull at 1 mm posterior to bregma and 4mm lateral to bregma. A
stainless steel hollow screw guide was screwed into the skull. A fiber optic cable
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(500 µm) was inserted into the screw guide and the incision was sealed back
together with vetbond. Blood pressure in the brain was then detected using the
Moor Instruments LTD laser Doppler with MoorLAB propriety Windows based
software on a standard laptop. Once surgery was complete, the screw guide
was removed and the scalp incision was closed with surgical sutures. Rats that
did not show ≥60% reduction in perfusion during MCAO were excluded from the
study.

Permanent Middle Cerebral Occlusion Model - Permanent focal ischemia was
achieved during MCAO by using the intraluminal suture technique. A 4cm long
monofilament was advanced up the internal carotid artery into the middle
cerebral artery and was then tied off at the internal/external carotid junction to
produce permanent occlusion. The incision was then sutured closed, given a
1ml subcutaneous injection of saline and allowed to wake in a fresh cage.

Brain Extraction and Sectioning - The animals were euthanatized with 0.5 ml
of pentobarbital at 96 hours, and perfused with saline and 4% paraformaldehyde.
The brains was harvested, post fixed in paraformaldehyde, and cryoprotected in
20% and 30% sucrose in PBS. Brains were frozen and sliced into 30µm
sections with a cryostat. Sections were either thaw mounted on glass slides or
placed in Walter’s Anti-freeze cryopreservative.
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Fluoro-Jade Histochemistry – Six coronal brain sections at 1 mm intervals
were cut from 1.7 to -3.3 mm from bregma were stained with Fluoro-Jade
(Histochem, Jefferson, AR), which labels degenerating neurons and is more
sensitive than triphenyltetrazolium chloride (TTC) in identifying
neurodegeneration. This method was adapted from that originally described by
Schmued et al (1997) and has been detailed previously by Duckworth et al
(2005). Tissue was thaw mounted and dried to glass slides. Slides were then
placed in absolute ethanol for 3 min followed by 70% ethanol and deionized
water for 1 min each. Sections were then oxidized using 0.06% KMnO4 solution
for 15 min followed by three rinses in ddiH2Ofor 1 minute each. Sections were
then placed in a 0.001% solution of Fluoro-Jade in 0.1% acetic acid for 30 min.
Slides were again rinsed, and then allowed to dry at 45 oC for 20 min, cleared
with xylene and coverslipped with DPX mounting medium (Electron Microscopy
Sciences, Ft. Washington, PA).

Nissl Staining with Thionin - Six coronal brain sections at 1 mm intervals were
cut from 1.7 to -3.3 mm from bregma were stained with Thionin (Sigma-Aldrich,
St. Louis, MO) which labels Nissl bodies in cells. Tissue was thaw mounted and
dried on glass slides. Slides were then dehydrated in alcohol series, stained in
the Thionin stock solution for 1.5 minutes, dehydrated, cleared with xylene and
coverslipped with Permount (Fisher Scientific, Fair Lawn, NY).
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Immunohistochemistry - The tissue slides were thawed, rinsed with PBS (pH
7.2), and then placed in permeabilization buffer containing 10% goat serum, 3%
1M lysine, and 0.3% Triton X-100 in PBS for 1 hr at room temperature. Next, the
sections were stained with either Isolectin IB4 (Griffonia simplicifolia) conjugated
to Alexa-Fluor® 488 (5 µl/ml, Molecular Probes, Eugene, OR) or
myeloperoxidase (MPO) rabbit polyclonal antibody (1:400, Affinity Bioreagents,
Golden,CO) overnight at 4°C in a PBS solution with 2% goat serum and 0.3%
Triton X-100 in a foil covered humidified chamber. The next morning the slides
were washed with PBS (3 x 5 min). The MPO slides were then incubated with
Alexa-Fluor® 488 goat anti-rabbit secondary (1:300, Molecular Probes) antibody
solution (PBS, 2% goat serum, 0.3% Triton X-100) in a foil covered humidified
chamber for 1 hour. The isolectin slides required no additional incubation step.
After final washing the slides were cover slipped with Vectashield hard set
mounting media with DAPI (Vector Laboratories, Burlingame, CA).

Infarct Volume Quantification - Images of six 30 µm brain sections were taken
at millimeter intervals from 1.7 to -3.3 mm from bregma to determine the volume
of infarction. The Fluoro-Jade stained tissue was digitally photographed with an
Olympus IX71 microscope controlled by DP manager software (Olympus
America Inc, Melville, NY) at a magnification of 1.25X. Images were edited with
Jasc Paintshop Pro. Area of neurodegeneration was measured using the NIH
Image J software. The area of the contralateral side of the brain tissue was also
measured and used to compensate for possible edema in the ipsilateral
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hemispheres. Infarct volumes were then calculated by the summation of the
infarct areas.

Blood Smear Preparation and Giemsa Staining – During harvest, a small drop
of blood was placed near the frosted end of a clean glass slide. A second slide
was used as a spreader. Holding the spreader slide at a 30 degree angle, the
spreader was drawn back against the drop of blood. The blood was then pulled
to the opposite edge of the slide producing a thin film on the slide. After air
drying and the smears were fixed in Methanol for 5 minutes and again allowed to
air dry. For Giemsa (Sigma-Aldrich) staining, slides were first washed three
times for 2 minutes each with distilled water. Slides laying flat were then flooded
with Giemsa stain (1 to 2 ml) for 4 minutes. Equal volumes of distilled water
were added to the slides to stop staining. Slides were then dunked in a large
container of water to remove excess stain. Stained slides were rinsed thoroughly
three times for three minutes in distilled water, air dried vertically overnight and
coverslipped with Permount.

Statistical Analysis - Infarct size was analyzed using ANOVA followed by
Bonferroni’s or Tukey’s post hoc tests. A value of p<0.05 was considered
significant.
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Results
Splenectomy Prior to MCAO Reduces Neurodegeneration
A hallmark of certain brain injury models is the infiltration of peripheral immune
cells that work to remove damaged tissue from the CNS (Stoll et al. 1998). A
high concentration of these cells, however, will often times result in enhanced
damage instead of aid through the release of free radicals, inflammatory
cytokines, chemokines and cytotoxic substances (Raivich et al. 1999; Stoll et al.
2000) as these immune cells are responding to the ischemic injury as if it were
invading pathogens. In conjunction with the increased peripheral immune cells
infiltrating the brain, it has been observed that the spleen, an organ related to the
immune system, shrinks in size. To determine whether the physiological change
of the spleen is contributing to increased peripheral immune cell activity in the
brain, as well as the neurodegeneration occurring at the site of ischemic injury,
we compared rats that underwent splenectomy followed two weeks later by
MCAO or sham MCAO with naïve rats that had MCAO only or sham MCAO. At
96 hours post-MCAO the animals were perfused, brains were sectioned at 30
µm, and infarct volume determined either with Fluoro-Jade, a histological stain
that labels degenerating neurons and Thionin, a histological stain that labels the
Nissl bodies of intact neurons.
In rats subjected to stroke-only, the Fluoro-Jade stain labeled extensive
degeneration in the cortex, striatum and hippocampus of the hemisphere
ipsilateral to the MCAO surgery (Figure 8a, center panel). Brain sections from
rats that underwent splenectomy prior to MCAO displayed significantly less
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Fluoro-Jade staining in the stroked side relative to brain sections of MCAO-only
rats (Figure 8a, center and right panels) and more closely resembled Fluoro-Jade
stained brain tissue from the sham MCAO animals (Figure 8a, left panel).
Quantification of the Fluoro-Jade stained infarct volumes demonstrated that the
splenectomy prior to MCAO significantly decreased infarct volume by 82.3%
compared to volumes from the brains of rats subjected to MCAO-only (*p<0.001;
significance determined by ANOVA followed by Dunn’s post hoc test) (Figure 8c)
To confirm these results we employed another method to measure infarct
size by labeling Nissl bodies of intact neurons with Thionin. In contrast to FluoroJade, absence of staining denotes neurodegeneration and cell death in the brain
section. Again we observed the same effects of splenectomy on stroke; the brain
sections of the MCAO-only treated rat showed absence of staining across the
majority of the ipsilateral hemisphere including the cortical, striatal and
hippocampal regions (Figure 8b, center panel). The brain sections from animals
subjected to splenectomy and stroke showed a uniform labeling of Nissl bodies
across the tissue, similar to brain sections from sham-operated rats, with only
minute areas deficient in staining (Figure 8b, left and right panels). Infarct
volume analysis again showed a significant decrease of 80.8% in those animals
whose spleens were removed before stroke (*p<0.001; significance determined
by ANOVA followed by Bonferroni’s post hoc test) (Figure 8d). Taken together,
the data gathered from these neuronal stains shows that the presence of the
spleen at the time of stroke contributes to the neurodegeneration occurring at the
site of ischemic injury.
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Splenectomy Modulates Peripheral and Systemic Immune Responses
Microglia, infiltrating macrophages, and neutrophils all enhance
neuroinflammation at the site of ischemia (Allan and Rothwell 2003; Barone and
Feuerstein 1999; Barone et al. 1995; Lucas et al. 2006). These cells may be
released from the spleen into the circulation during size reduction in response to
stroke injury. We, therefore, examined this inflammatory response in the brain
with immunohistochemical stains for activated microglia and peripheral immune
cells.
We first investigated microglia, the resident macrophages of the brain that
lie dormant in a ramified state until activated by some insult (Allan and Rothwell
2003; Lyons et al. 2000) and systemic macrophages, which are chemically called
to the ischemic injury and invade through a compromised blood brain barrier
(Kim et al. 2006; Stoll et al. 2002). To this date these cell types are not readily
distinguishable due to lack of differential cellular markers and act in similar
fashion in their expression of chemokines, inflammatory cytokines and free
radical production (Raivich et al. 1999). To observe the actions of these cells in
response to splenectomy and stroke, we labeled the cells with Isolectin IB4 which
binds sugar residues found on activated microglia, infiltrating macrophages, and
endothelial cells. The morphology of the immune cells, however, is easily
discerned from that of the endothelial cells (Abbott 2000; Kim et al. 2006). Brain
sections of MCAO-only rats showed cell labeling in the ipsilateral hemisphere
(Figure 9b). Brain sections from splenectomized rats show Isolectin labeling of
activated microglia and macrophages in small localized regions within the cortex
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and striatum (Figure 9c). In sham rat tissue only endothelial cells of the blood
vessels and intact fiber tracts were labeled for background staining (Figure 9a)
Neutrophil granulocytes, part of the innate immune system, are reported to
be one of the first damaging cell types present in the infarction and are involved
in the exacerbating neurodegeneration resulting from stroke (Akopov et al. 1996;
Barone and Feuerstein 1999; Emerich et al. 2002; Zhang et al. 1994a). Inhibition
of neutrophils at the time of stroke has also shown apromising reduction of
infarction (Chen et al. 1994; Chopp et al. 1994). These cells adhere to
endothelium (Barone and Feuerstein 1999), release inflammatory cytokines, and
chemoattractants (Barone and Feuerstein 1999) and produce radicals resulting in
tissue damage (Dirnagl et al. 1999; Iadecola and Alexander 2001; Matsuo et al.
1995; Matsuo et al. 1996). Since these innate immune cells are found in the
brain during ischemic injury and have been reported to reside in the spleen (Shi
et al. 2001) neutrophils, as affected by splenectomy and MCAO, were discerned
by immunohistochemically labeling brain sections for myeloperoxidase (MPO), a
peroxidase enzyme found in lysosomes of these cells (Feuerstein et al. 1998;
Nauseef 1998; Weston et al. 2006). Brain tissue sections of rats that were
subjected to MCAO-only showed an increase of MPO labeling and a
disappearance of fiber tracks in the infarct at the level of the striatum (Figure
10b). Tissue sections from splenectomized rats that underwent MCAO showed
few MPO stained cells comparable to tissue sections from sham rats (Figure 10a
and 10c). Labeled neutrophil analysis showed a significant decrease of 90.1% in
MPO labeled cells in the brain tissue of splenectomized rats that underwent
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stroke (*p<0.001, significance determined by ANOVA followed by Dunn’s post
hoc test) (Figure 10d). These results indicate that the spleen modulates the
systemic immune response occurring at the site of ischemic injury and may be a
reservoir for peripheral immune cells which are released at the time of cerebral
injury and migrate to the brain exacerbating damage.

Splenectomy has no Effect on Peripheral White Blood Cell Populations
Since infiltrating peripheral immune cells travel through the vasculature migrating
to the damaged tissue in the brain (Lucas et al. 2006), we examined whether
spleen removal altered the profile of leukocytes in the blood. Smears were
obtained from all rats at 0, 48, and 96 hours after the stroke surgery. These
blood smears were stained with Giemsa and white blood cell populations
tabulated. In the stroke-only animals blood leukocytes did not significantly
change in the blood at 48 and 96 hours (Figure 11a).
In those animals that had their spleens removed prior to the stroke
surgery, there was no significant change in the white blood cell populations in the
blood post-MCAO. There was a tendency for the lymphocyte population to
decrease and the neutrophil population to increase at 48 hours but both of these
cell types returned to baseline levels at 96 hours but these changes were not
significant (Figure 11b). Sham MCAO (Figure 11c) and splenectomy sham
MCAO (Figure 11d) blood smears demonstrated no change in blood cell
populations. Blood smears taken during the two week recovery period and
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stained with Giemsa showed no significant change in leukocyte populations as a
result of splenectomy (Figure 11e).

Discussion
Our results show that splenectomy prior to stroke significantly reduces infarction
size in the brain. A proposed mechanism of action is activation of the
sympathetic nervous system when a stroke occurs resulting in spleen reduction
through a potential release of red and white blood cells (Stewart and McKenzie
2002). This reduction causes a release of pro-inflammatory immune cells, which
are attracted to the brain by chemokines where they increase neuroinflammation
and neurodegeneration (Abraham et al. 2002; Hausmann et al. 1998). Removal
of the spleen prior to stroke decreases the peripheral immune cells entering the
brain through a compromised blood brain barrier resulting in decreased
neuroinflammation and neurodegeneration. This is consistent with the data
reported from the transfusion of HUCBC into stroked rats (Offner et al. 2006b;
Vendrame et al. 2006).
Alternatively, these data also yield insight into the systemic nature of the
body’s response to a brain injury. Activated microglia have been thought to be
the main cause of the second wave of neurodegeneration in the infarct area as
these cells have been shown to outnumber the macrophages at the infarction
(Liu and Hong 2003; Schilling et al. 2003). However, systemic inhibition of
macrophages by anti-CD11b, anti-CD18, and anti-Mac-1 monoclonal antibodies
1 hour after transient middle cerebral artery occlusion show significant reduction
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of infarction volume in the ischemic brain (Chen et al. 1994; Chopp et al. 1994;
Zhang et al. 1995b). This suggests that the synergistic actions of both the
activated microglia and infiltrating macrophages result in the secondary
enhanced neuroinflammation and neurodegeneration. Splenectomy dramatically
reduces infarction demonstrating that inhibition of systemic immune response
cells by removing a population of infiltrating macrophages, neutrophils, B cells
and T cells reduces cellular interaction with the activated microglia at the site of
ischemic injury resulting in decreased damage.
We believe that the removal of the spleen does not result in a
preconditioning response that ultimately reduces infarction size in the rat. If this
were the case, removal of the spleen would result in an immune response in the
rat and yet white blood cell populations are stable during the two week recovery
period prior to stroke. In light of our findings of decreased infarct volume and
modulation of immune cells we strongly recommend further testing of the splenic
interaction with ischemic brain injury and propose that this organ is an excellent
target for developing novel treatments that will minimize stroke damage.

Acknowledgements This work was supported by grants from the National
Institute for Health NS052839-01A1 (to A.W.)

112

Chapter 2, Figure 8
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Figure 1: Histological pathology of infarct in brain tissue of
splenectomized rats 96hr post MCAO. a, Fluoro-Jade staining shows a large
area damage in the ipsilateral hemisphere (a, center panel) whereas
splenectomy reduces Fluoro-Jade labeled degenerating neurons (a, right panel)
and is similar in staining to sham tissue (a, left panel). b, The area lacking
Thionin staining in the brain section from the MCAO-only treated rat is
representative of the infarction (b, center panel) while tissue sections from sham
(b, left panel) and splenectomized rats (b, right panel) that were subjected to
stroke show reduced loss of staining (a and b scale bar = 5 mm). c, ANOVA
followed by the post hoc Dunn’s test showed that splenectomy significantly
reduced Fluoro-Jade stained degenerating neurons when performed prior to
stroke (*p<0.001). d, ANOVA followed by the post hoc Bonferroni’s test showed
that splenectomy significantly reduces absence of Thionin staining in brain
sections from rats that underwent stroke (*p<0.001).
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Figure 2: Immunohistochemical labeling of activated microglia and
infiltrating macrophages at the level of infarction 96 hours post MCAO. a,
Isolectin IB4 labeling shows no activated microglia or macrophages in brain
sections of sham operated rats. Arrows point to intact fasiculae of the striatum
that pick up background staining. b, Box denotes area labeled with Isolectin IB4
and shows activated microglia and macrophages. The arrow points to
endothelial cells of a blood vessel labeled by Isolectin IB4. c, Isolectin IB4
labeling of brain sections from splenectomized MCAO rats show reduced
microglia and macrophage activity and is localized to a smaller area seen inside
box. Scale bar = 400 µm
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Figure 3: MPO staining of neutrophils in the infarct zone. a,
Immunohistochemical labeling of brain sections for MPO shows no neutrophils in
the striatum of the sham rats; the arrow indicates fasiculae in the striatum were
intact. b, MPO staining in brain sections from rats treated with MCAO-only show
many neutrophils in the striatum and a disappearance of fasiculae. Arrows
denote labeled neutrophils. c, Brain sections from rats treated with splenectomy
prior to stroke show similar pathology to the sham brain section (panel a) with
intact fasiculae designated by arrow. Scale bars = 200 µm. d, ANOVA followed
by the post hoc Bonferroni’s test showed that splenectomy significantly reduces
average number of cells labeled with MPO that were counted in representative
areas of the infarction (*p<0.001).
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Figure 4: White blood cell profiles during treatments. a, White blood cell
profiles at 0, 48, and 96 hours after stroke for rats that underwent MCAO-only. b,
White blood cell profiles of splenectomized rats that were subjected to stroke
taken at 0, 48, and 96 hours after stroke. c, White blood cell profiles of sham
MCAO operated rats at 0, 48, and 96 hours after sham stroke. d, White blood
cell profiles of splenectomy sham MCAO operated rats at 0, 48 and 96 hours
after sham stroke. e, White blood cell profiles of the two week recovery period
between splenectomy and stroke. ANOVA followed by the post hoc Tukey’s test
showed no significant differences between the groups (*p<0.05).
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Abstract
Splenectomy two weeks prior to stroke results in a significant decrease in
infarct volume, and immune cell modulation in the rat brain parenchyma. Also
stroke itself causes splenic shrinkage suggesting that the spleen contributes the
mechanisms of damage occruing at the site of ischemic injury. To determine if
autonomic neurotransmission produces in the splenic response to stroke,
spleens of male Sprague-Dawley rats were isolated and denervated two weeks
prior to permanent middle cerebral artery occlusion (MCAO). At 48 hours after
the stroke surgery, blood and spleen tissue were harvested for flow cytometry
analysis and labeled with various leukocyte specific antibodies. At this time, the
rats were also perfused with 4% paraformaldehyde, brains were harvested,
sectioned at 30 µm, and labeled with markers of neurodegeneration and
inflammation. Flow cytometry analysis showed a significant increase in the
percentage of monocytes present in spleen samples from denervated rat spleens
compared to the spleens of rats subjected to MCAO-only. Flow cytometry
analysis showed no significant difference in all other cellular percentages when
comparing the blood and spleen tissue from the denervated rats to rats that
underwent MCAO-only. Infarct volume analysis by Fluoro-Jade, which labels
degenerating neurons, showed no significant changes in the volume of ischemic
damage in the brains of those rats whose spleens were denervated prior to
stroke when compared to infarct volumes in the brains of MCAO-only rat. This
previous observation was supported by thionin Nissl staining showing that
infarction from the denervated spleen sample group equaled those from MCAO-

127

only. Denervation of the spleen prior to stroke also failed to inhibit splenic
shrinkage. Weights of these spleens showed no significant difference from the
spleen weights of MCAO-only animals. These results indicate that splenic
shrinkage at the time of stroke is not contingent on autonomic neurotransmission.
This suggests that spleen shrinkage is not a result of direct signal transmission
from the splenic nerve.
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Introduction
Stroke causes several dysfunctions in autonomic control that can lead to
hypertension, arrhythmias, myocardial necrosis and death (Meyer et al. 2004).
These alterations become most prevalent during the acute or early phase of
stroke where sympathetic neurotransmission is up-regulated (Tokgozoglu et al.
1999; Wang et al. 1997). Shortly after ischemic insult, there is an increase of
both norepinephrine and epinephrine in the circulation which are sympathetic
neurotransmitters (Meyer et al. 2004). Activation of α adrenergic receptors by
these agonists results in elevated heart rate by cardiac muscle contraction and
hypertension by vascular smooth muscle contraction (Butcher et al. 1993;
Cechetto et al. 1989; Klingelhofer and Sander 1997). The spleen may be
affected by this increase in sympathetic tone as it has been shown that the
splenic nerve is composed of approximately 98% sympathetic nerve fibers (Klein
et al. 1982) and most studies involving the autonomic nervous system and the
spleen suggest that innervation is predominantly sympathetic (Elenkov et al.
2000). Splenic smooth muscle has also been shown to contract, which is
facilitated by sympathetic neurotransmission and to autotransfuse large amounts
of red blood cells into the circulation during times of physiological stress (Stewart
and McKenzie 2002).
Recent studies transfusing human umbilical cord blood cells (HUCBC)
have showed that therapeutic window of treatment can be extended up to 48
hours after permanent middle cerebral artery occlusion (MCAO) (Newcomb et al.
2006; Vendrame et al. 2004). This treatment elevates neuroprotective and anti-
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inflammatory effects resulting in significant decreases in infarction volume in the
rat brain (Vendrame et al. 2004). PCR analysis for human DNA of the cord blood
cells showed that they migrated only to the injured hemisphere of the brain and
the spleen when transfused 24 hours after MCAO (Vendrame et al. 2004).
Identification of HUCBC by immunoreactivity for human nuclei confirmed the
presence of the HUCBC in the spleen (Vendrame et al. 2004). Further
investigation of the spleen/stroke interaction showed that the spleen shrinks in
response to ischemic injury; this is accompanied by an increase of regulatory T
cells and macrophages in the circulation (Offner et al. 2006b) suggesting that the
spleen contributes to the peripheral immune response of stroke by releasing
stored inflammatory cells which then infiltrate the brain and enhance
inflammation and neurodegeneration at the site of injury.
Our laboratory has shown that removal of the spleen two weeks prior to
MCAO in rats results in a >80% decrease in infarction. This effect was
accompanied by a significant reduction in the number of infiltrating neutrophils
and decreased activated microglia/macrophages. These results confirm that the
spleen contributes to stroke-induced neurodegeneration and supports the
hypothesis that the spleen is a target for developing alternative treatments for
stroke that can modulate neurodegeneration and inflammation. Determination of
the signaling mechanism that initiates splenic reaction to stroke is vital to
inhibiting the splenic response to ischemia. We hypothesize that sympathetic
neurotransmission is the signaling mechanism that causes the spleen to shrink,
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releasing inflammatory factors that contribute to the neurodegeneration occurring
at the site of injury.
By examining the effects of denervation of the spleen prior to stroke on
histological and immunohistochemical markers of neurodegeneration and flow
cytometry analysis of leukocyte profile, we show that splenic reaction to stroke is
not dependent on sympathetic innervation. These findings imply that another
mechanism of action creates the link between ischemic injury and splenic
shrinkage.

Materials and Methods
Animals - Male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 300 to
350 g were housed in a climate controlled room with water and laboratory chow
available ad libidum. Animals were cared for according to the guidelines of the
IACUC of the University of South Florida’s College of Medicine.

Splenic Denervation – Rats were anesthetized with 3 to 4% isofluorane and
maintained with 100% oxygen with. Denervation was performed by making a 4
cm dorsal midline skin incision at the caudal terminus at the level of the 13th rib.
Opening the abdominal wall on the anatomical left, 1.5 to 2.5 cm from midline
exposed the spleen. With blunt forceps, the organ, (with accompanying blood
vessels and adipose tissue), was exteriorized through the incision. Under a
surgical microscope, splenic nerves were located at the anterior and posterior
underside of the spleen and ligated taking care not to damage the splenic blood
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vessels. The spleen and adipose tissue were then reinserted into the animal
through the incision which was then closed with suture.

Splenectomy – Male Sprague-Dawley rats weighing 300 to 350 g were
anesthetized and maintained with 3 to 4% isofluorane in 100% oxygen.
Splenectomy was performed by making a 2 cm dorsal midline skin incision in the
rat at the caudal terminus at the level of the 13th rib. Opening the abdominal wall
on the anatomical left, 1.5 to 2.5 cm from midline exposed the spleen. With blunt
forceps, the organ, (with accompanying blood vessels and pancreatic tissue),
was exteriorized through the incision. The blood vessels were ligated; the spleen
was removed and stored at -80°C. The skin incision was closed with 3-0 sutures.

Laser Doppler Radar Blood Flow Measurement – Rats were anesthetized and
maintained with 3 to 4% isofluorane in 100% oxygen, The rat’s head and neck
were shaved. Using a scalpel, an incision was made to expose the plates of the
skull on the side that was ipsilateral to the MCAO. Once the incision was made,
the skin was spread open and the membrane covering the skull pushed aside by
rubbing with a cotton tipped applicator. Using a microdrill a small hole was drilled
through the skull at 1 mm posterior to bregma and 4mm lateral to bregma. A
stainless steel hollow screw guide was screwed into the skull. A fiber optic cable
(500 µm) was inserted into the screw guide and the incision was sealed back
together with vetbond. Blood pressure in the brain was then detected using the
Moor Instruments LTD laser Doppler with MoorLAB propriety Windows based
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software on a standard laptop. Once surgery was complete, the screw guide
was removed and the scalp incision was closed with surgical sutures. Rats that
did not show ≥60% reduction in perfusion during MCAO were excluded from the
study.

Permanent Middle Cerebral Occlusion Model - Permanent focal ischemia was
achieved during MCAO by using the intraluminal suture technique. A 4cm long
monofilament was advanced up the internal carotid artery into the middle
cerebral artery and was then tied off at the internal/external carotid junction to
produce permanent occlusion. The incision was then sutured closed, given a
1ml subcutaneous injection of saline and allowed to wake in a fresh cage.

Brain Extraction and Sectioning - The animals were euthanatized with 0.5 ml
of pentobarbital at 96 hours, and perfused with saline and 4% paraformaldehyde.
The brains were harvested, post fixed in paraformaldehyde, and cryoprotected in
20% and 30% sucrose in PBS. Brains were frozen and sliced into 30µm
sections with a cryostat. Sections were either thaw mounted on glass slides or
placed in Walter’s Anti-freeze cryopreservative.

Fluoro-Jade Histochemistry – Six coronal brain sections at 1 mm intervals
were cut from 1.7 to -3.3 mm from bregma were stained with Fluoro-Jade
(Histochem, Jefferson, AR), which labels degenerating neurons and is more
sensitive than triphenyltetrazolium chloride (TTC) in identifying
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neurodegeneration. This method was adapted from that originally described by
Schmued et al (1997) and has been detailed previously by Duckworth et al
(2005). Tissue was thaw mounted and dried to glass slides. Slides were then
placed in absolute ethanol for 3 min followed by 70% ethanol and deionized
water for 1 min each. Sections were then oxidized using 0.06% KMnO4 solution
for 15 min followed by three rinses in ddiH2Ofor 1 minute each. Sections were
then placed in a 0.001% solution of Fluoro-Jade in 0.1% acetic acid for 30 min.
Slides were again rinsed, and then allowed to dry at 45 oC for 20 min, cleared
with xylene and coverslipped with DPX mounting medium (Electron Microscopy
Sciences, Ft. Washington, PA).

Nissl Staining with Thionin - Six coronal brain sections at 1 mm intervals were
cut from 1.7 to -3.3 mm from bregma were stained with Thionin (Sigma-Aldrich,
St. Louis, MO) which labels Nissl bodies in cells. Tissue was thaw mounted and
dried on glass slides. Slides were then dehydrated in alcohol series, stained in
the Thionin stock solution for 1.5 minutes, dehydrated, cleared with xylene and
coverslipped with Permount (Fisher Scientific, Fair Lawn, NY).

Immunohistochemistry - The tissue slides were thawed, rinsed with PBS (pH
7.2), and then placed in permeabilization buffer containing 10% goat serum, 3%
1M lysine, and 0.3% Triton X-100 in PBS for 1 hr at room temperature. Next, the
sections were stained with either Isolectin IB4 (Griffonia simplicifolia) conjugated
to Alexa-Fluor® 488 (5 µl/ml, Molecular Probes, Eugene, OR) or
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myeloperoxidase (MPO) rabbit polyclonal antibody (1:400, Affinity Bioreagents,
Golden,CO) overnight at 4°C in a PBS solution with 2% goat serum and 0.3%
Triton X-100 in a foil covered humidified chamber. The next morning the slides
were washed with PBS (3 x 5 min). The MPO slides were then incubated with
Alexa-Fluor® 488 goat anti-rabbit secondary (1:300, Molecular Probes) antibody
solution (PBS, 2% goat serum, 0.3% Triton X-100) in a foil covered humidified
chamber for 1 hour. The isolectin slides required no additional incubation step.
After final washing the slides were cover slipped with Vectashield hard set
mounting media with DAPI (Vector Laboratories, Burlingame, CA).

Infarct Volume Quantification - Images of six 30 µm brain sections were taken
at millimeter intervals from 1.7 to -3.3 mm from bregma to determine the volume
of infarction. The Fluoro-Jade stained tissue was digitally photographed with an
Olympus IX71 microscope controlled by DP manager software (Olympus
America Inc, Melville, NY) at a magnification of 1.25X. Images were edited with
Jasc Paintshop Pro. Area of neurodegeneration was measured using the NIH
Image J software. The area of the contralateral side of the brain tissue was also
measured and used to compensate for possible edema in the ipsilateral
hemispheres. Infarct volumes were then calculated by the summation of the
infarct areas.

Flow Cytometry – Spleen and blood samples were both processed for flow
cytometry analysis. The spleen was removed from the rat prior to perfusion. It
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was then placed in a stomacher bag containing 15 ml of ice cold PBS pH 7.4 with
0.2% BSA (PBS/BSA). The spleen was then mashed with a stomacher and the
suspension was drained through a 40µm cell strainer into a 50ml conical tube.
Volume was brought up to 15ml with PBS/BSA and then centrifuged at 1500 rpm
for 10 minutes at room temperature. Supernatant was removed and the pellet
was resuspended in 0.5ml ACK lysis buffer (4.01g NH4Cl + 0.5g KHCO3 + 0.01g
EDTA in 500ml ddiH20) for 5 minutes. The solution was then diluted in 1ml
PBS/BSA and spun at 1500 rpm for 10 minutes. Supernatant was removed and
the pellet was resuspended in 2ml PBS/BSA.
For blood preparation, 1 ml of blood was removed from the rat just prior to
perfusion. The blood was then added to a tube containing 1ml of Dextran
solution (10 mM EDTA + 1% Dextran (Mw 400,000 – 500,000) in 500ml of PBS
pH 7.4) and was allowed to incubate at 37 oC for 1 hour. Supernatant was
removed and diluted with 1ml PBS/BSA and spun at 15 rpm for 10 minutes.
Supernatant was removed and the pellet was resuspended in 0.5 ml ACK lysis
buffer for 5 minutes. The solution was then diluted with 1ml PBS/BSA and spun
at 1500 rpm for 10 minutes. Supernatant was removed and the pellet was
resuspended in 2ml PBS/BSA. Cells were counted using a hemocytometer and
Trypan Blue exclusion method At least 106 cells were aliquoted into 100 µl of
PBS/BSA. Aliquots then received 20 µl of Fc Block per 100 µl and were
incubated in solution for 10 minutes in ice. Antibodies were then added and
allowed to incubate for 15 – 30 minutes. Aliquots were then centrifuged, washed
with PBS/BSA and the process repeated to remove excess antibody.
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Analysis of staining was performed at the Moffitt Cancer Center flow
cytometry core center in Tampa, Florida. At this core facility 5000 events were
counted from the aliquots, cellular populations were identified based on staining
profile, and percentages of these populations were determined.

Blood Smear Preparation and Giemsa Staining – During harvest, a small drop
of blood was placed near the frosted end of a clean glass slide. A second slide
was used as a spreader. Holding the spreader slide at a 30 degree angle, the
spreader was drawn back against the drop of blood. The blood was then pulled
to the opposite edge of the slide producing a thin film on the slide. After air
drying and the smears were fixed in Methanol for 5 minutes and again allowed to
air dry. For Giemsa (Sigma-Aldrich) staining, slides were first washed three
times for 2 minutes each with distilled water. Slides laying flat were then flooded
with Giemsa stain (1 to 2 ml) for 4 minutes. Equal volumes of distilled water
were added to the slides to stop staining. Slides were then dunked in a large
container of water to remove excess stain. Stained slides were rinsed thoroughly
three times for three minutes in distilled water, air dried vertically overnight and
coverslipped with Permount.

Statistical Analysis - Infarct size, spleen weight, and % of blood cell populations
were analyzed using ANOVA followed by Bonferroni’s or Tukey’s post hoc tests.
A value of p<0.05 was considered significant.
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Results
Denervation Prior to MCAO does not Inhibit Splenic Response
To determine whether sympathetic neurotransmission was modulating the
physical size reduction of the spleen at the time of stroke, we looked at spleen
weight changes at the time of stroke. We compared spleens of rats that were
subjected to splenic denervation prior to MCAO to those rats that underwent
MCAO only, sham-MCAO, and denvervated spleen/sham-MCAO (Figure 12).
Analysis of the spleen weights of these groups showed that denervated spleens
of rats subjected to stroke had a significantly smaller weight when compared to
sham-MCAO and denervated spleen/sham-MCAO (p<0.05) (Figure 12). There
was no significant difference in the size of the spleens from the denervated
spleen-MCAO and MCAO-only treatment groups. These results indicate that
direct sympathetic innervation via the splenic nerve does not result in splenic
shrinkage that is observed after stroke.

Splenic Denervation Prior to MCAO does not affect Infarct Volume
We have previously determined that splenectomy prior to stroke results in a
significant reduction in neurodegeneration at the site of ischemic injury. To
determine if lack of neuronal signaling was the reason why splenectomy resulted
in a decrease in infarction volume, we compared denervated spleen/MCAO with
spleens of rats that received splenectomies two weeks prior to MCAO as another
form of control.
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Fluoro-Jade extensively labeled degenerating neurons in the cortex,
striatum and hippocampus of the hemisphere ipsilateral to the stroke in the
brains of rats subjected to MCAO-only (Figure 13). Brain sections of rats that
underwent splenic denervation two weeks prior to stroke showed a similar
pattern of Fluoro-Jade labeling as observed in the rats subjected to MCAO-only.
Splenectomy prior to stroke again showed reduced Fluoro-Jade staining of the
brain parenchyma. Quantification of the infarction volumes revealed no
significant difference in volumes between the denervated spleen-MCAO and
MCAO-only groups. Splenectomy prior to stroke resulted in led to a significant
decrease in infarct volume when compared to the volumes in denervated spleenMCAO and MCAO-only rats (p<0.05) (Figure 15a).
To confirm these results we employed another method to measure infarct
size by labeling Nissl bodies of intact neurons with Thionin. In contrast to FluoroJade, absence of staining denotes neurodegeneration and cell death in the brain
section; even so the results were similar. MCAO only-treated rats and
denervated spleen-MCAO rats showed an absence of Nissl staining across the
majority of the ipsilateral hemisphere including the cortical, striatal and
hippocampal regions (Figure 14). Splenectomy prior to stroke decreased
neurodegeneration in the brain sections as demonstrated by increased of
labeling of the Nissl bodies of neurons. When we quantified and analyzed the
infarct volumes there was no significant differences between MCAO-only and
denervated spleen-MCAO group infarct volumes while the infarct volumes of rats
whose spleens were removed prior to stroke again showed a significantly lower
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average infarct volume when compared to the afore mentioned experimental
groups (Figure 15b). These results indicate that while the spleen contributes to
stroke-induced neurodegeneration, elimination of sympathetic neurotransmission
in the spleen does not mimic the neuroprotective effects seen with splenectomy
prior to stroke.

Flow Cytometry Analysis Shows Increased Splenic Monocytes
To determine if denervation affected cell populations blood and spleen, tissue
samples were analyzed by cytometry. Monocytes, neutrophils, B cell and T cell
surface antibodies were used to label the individual cell types for analysis.
Cytometry analysis showed that there was a significant increase in the
percentage of CD4+ labeled monocytes in those spleens subjected to
denervation prior to stroke when compared to the percentage of CD4+ cells
found in the spleens of rats subjected to MCAO-only (Figure 16). Flow cytometry
analysis showed no other significant differences in all other cellular
compartments of blood and spleen tissue from the denervated rats compared to
rats that underwent MCAO-only (Figures 16 and 17).

Denervation has no Effect on Giemsa Stained Leukocyte Populations after
MCAO
Peripheral immune cells have been shown to travel through the vasculature,
infiltrate the brain and migrate to the site of damage after ischemic insult. While
our laboratory has previously shown that splenectomy has no affect on leukocyte
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populations after stroke, we examined if spleen presence and inhibition of
sympathetic neurotransmission would result in cell population alterations. Blood
smears were obtained at 0 and 48 hours after stroke surgery, stained with
Giemsa and white blood cell profiles were tabulated. While cell populations
changed from 0 to 48 hours in each group we were interested in how treatment
affected the populations at 48 hours after MCAO. We found that there were no
significant differences between experimental groups as lymphocytes, monocytes
and neutrophils all showed the same cellular population alterations between the
sham-MCAO, denervated spleen/sham-MCAO, denervated spleen MCAO,
splenectomy MCAO, and MCAO alone (Figure 18).

Discussion
In response to stroke, the periphery reacts by increasing cardiac
contraction and vasoconstriction which can potentially lead to cardiac arrhythmia
and hypertension (Klingelhofer and Sander 1997). These responses have been
shown to be a result of increased sympathetic neurotransmission as a response
to the injury that has occurred in the brain (Butcher et al. 1993; Cechetto et al.
1989; Klingelhofer and Sander 1997). While sympathetic neurotransmission is
driving many of the peripheral processes after stroke, our results show that
denervation of sympathetic neurotransmission to the spleen has no affect on
splenic contribution to stroke-induced neurodegeneration. We hypothesized that
removal of the splenic innervation would inhibit sympathetic neurotransmission to
the spleen resulting in organ size retention, and decreased neurodegeneration
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and inflammation at the time of ischemic injury. During stroke there is a
substantial increase of epinephrine and norepinephrine that is released from the
adrenal gland into the circulation that activates sympathetic tone (Rosol et al.
2001; Wong 2006). While the sympathetic nerves to the spleen have been
removed, it is quite possible that these neurotransmitters are still reaching the
spleen through the circulation where they can bind to the adrenergic receptors
located on the smooth muscle capsule and splenocytes of the spleen, causing
contraction and spleen shrinkage.
Flow cytometry analysis of spleen tissue for different molecular markers of
leukocytes showed a significant increase only in the percentage of macrophages
in denervated spleens. Membranes of blood monocytes are shown to highly
express the β2 adrenergic receptor. In most studies activation of the β2 receptor
by an agonist, such as epinephrine, has been shown to be immunosuppressive
by inhibiting the release of proinflammatory cytokines and down regulating the
expression of intracellular monocyte adhesion molecules on monocyte cell
surfaces (Kuroki et al. 2004; Mizuno et al. 2005). This suggests that removal of
sympathetic innervation to the spleen decreases anti-inflammatory effects of β2
agonist receptor activation allowing for the potential increased macrophage
activity observed in the spleen. Denervation of the spleen may also systemically
signal an injury to the organ resulting in the increased proliferation of blood
monocytes. In light of our findings of the lack of sympathetic neurotransmission
contribution to splenic response to stroke, we strongly recommend further testing
of the splenic interaction with ischemic brain injury for the purpose of determining
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the mechanism of action for the development of alternative that will decrease
neurodegenerative and inflammatory effects of stroke.
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Figure 1: Denervation has no effect on spleen shrinkage resulting from
stroke. Spleens of rats subjected to denervation prior to stroke showed reduced
weight when removed at 48hours after stroke. ANOVA followed by the post hoc
Dunnett’s test showed that there was no significant difference between
denervated spleen weight and the weights of spleens taken from rats subjected
to MCAO-only.

145

Chapter 3, Figure 13

A

B

C

D

146

Figure 2: Fluoro-Jade labeled neurodegeneration in brain tissue of
denervated rats 48hr post MCAO. There was a large area of damage as
indicated by Fluoro-Jade labeled cellsin the ipsilateral hemisphere of rats whose
spleens were denervated prior to stroke (panel d), which was similar to the
Fluoro-Jade labeled neurodegeneration in the ipsilateral hemisphere in rats
subjected to MCAO-only (panel c). Sham-MCAO (panel a) and denervated
spleen/sham-MCAO (panel b) had little Fluoro-Jade labeled neurodegeneration.
(a and c scale bar = 5 mm) (b and d scale bar = 2 mm)
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Figure 3: Thionin labeling of Nissl bodies of surviving brain tissue of
denervated rats 48hr post MCAO. Tissue lacking staining is indicative of the
infarction. Similar lack of tissue staining shows large infarct areas in both
denervated spleen MCAO brain tissue (panel d) and MCAO only brain tissue
(panel c). Sham-MCAO (panel a) and devervated spleen/sham-MCAO (panel b)
showed no Fluoro-Jade labeled neurodegeneration. Tissue sections from
Sham-MCAO (panel a) and denervated spleen/Sham-MCAO (panel b) showed
no loss of Thionin staining (b scale bar = 5 mm) (a, c and d scale bar = 2 mm)
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Figure 4: Analysis of infarction volumes labeled by histological staining.
a, ANOVA followed by the post hoc Bonferroni’s test showed that denervation of
the spleen prior to stroke produced no significant difference in the average
infarction volume of the brain tissue determined with Fluoro-Jade labeling
compared to average infarction volume of rats subjected to MCAO only. Analysis
did show that splenectomy prior to stroke significantly reduced average FluoroJade stained infarction volume compared to the average infarct volumes from the
brain of rats that underwent denervation of the spleen prior to MCAO and MCAO
only. (*p<0.05) b, ANOVA followed by the post hoc Bonferroni’s test of average
infarct volumes determined from Thionin staining shows that there was no
significant difference between average volumes from denervated spleen/MCAO
compared to MCAO only. Splenectomy prior to MCAO significantly reduced
infarct volume compared to denervated spleen/MCAO and MCAO only infarct
volumes. (*p<0.05)

151

152
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Figure 5: Flow cytometry analysis of spleen homogenates.
a, Flow cytometry analysis of T cells positive for the CD3 antibody showed no
significant difference in percentage of cell populations across experimental
groups. b, There was no significant difference in the percentage of helper T cell
populations stained with the CD4 antibody. c, There was no significant
difference in the percentage of cytotoxic T cells labeled by CD8a. d, Flow
cytometry analysis of B cells stained positive for the CD45R showed no
significant changes in the percentage of cells in the populations. e, Neutrophils
labeled with the HIS48 antibody showed no changes in the percentage of cells in
the population. f, Flow cytometry analysis of monocytes labeled with the CD4
antibody showed a significant increase in the percentage of positively stained
cells in the population in the spleen homogenates from the denervated
spleen/MCAO group when compared to those of the MCAO only group (*p<0.01).
Significance was determined by ANOVA followed by the post hoc Bonferroni’s
test.
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Figure 6: Flow cytometry analysis of blood samples.
a, Flow cytometry analysis of T cells stained positive for the CD3 antibody
showed no significant difference in percentage of cell populations across
experimental groups. b, There was no significant difference in the percentage of
helper T cell populations stained with the CD4 antibody. c, There was no
significant difference in the percentage of cytotoxic T cells labeled by CD8a. d,
Flow cytometry analysis of B cells stained positive for the CD45R showed no
significant changes in the percentage of cells in the populations. e, Neutrophils
labeled with the HIS48 antibody showed no changes in the percentage of cells in
the population. f, Flow cytometry analysis of monocytes labeled with the CD4
antibody showed no significant changes in the percentage of labeled cells within
the population. Significance was determined by ANOVA followed by the post hoc
Bonferroni’s test. Absence of data in b and f suggest malfunction in staining
process prior to flow cytometry analysis.
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Figure 7: Analysis of blood smear white blood cell populations by Giemsa
staining. Analysis of white blood cell populations at 48 hours after MCAO
showed no significant changes in lymphocyte (a), monocyte (b), and neutrophil
(c), populations. Significance was determined by ANOVA followed by the post
hoc Bonferroni’s test.
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CONCLUSION
During embolic stroke, an obstruction of blood flow, reduced nutrients and failure
of energy production results in progressive damage to the central nervous
system. Depending on the severity of these homeostatic alterations, stroke can
lead to death, or severe physical and mental disabilities that require specialized
care (W.H.O. 2007). The sole treatment for ischemic stroke is recombinant
tissue plasminogen activator (rtPA). This treatment can restore blood flow to the
injured brain by dissolving the embolus Only 13% of the time (Albers et al. 2004).
The major caveat to this treatment is that it must be administered within 3 hours
of stroke onset or 6 hours after stroke when intra-arterially dispensed (Albers et
al. 2004; Marler and Goldstein 2003). This treatment may also produce adverse
effects related to its mechanism of action such as intracranial bleeding and the
production of oxygen free radicals. Thus, rtPA can only be administered to a
select group of stroke victims that are diagnosed during this time period that
meet specific criteria for this therapy (Albers et al. 2004). The rtPA must be used
within such a short time period because it can cause intracranial bleeding.
Therefore, rtPA must be administered prior to the induction of neurodegenerative
cascades and the inflammatory response. There has been increasing evidence
that any treatment of stroke at delayed timepoints must decrease the
inflammatory response in addition to treating neurodegeneration (Newcomb et al.
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2006; Vendrame et al. 2004). Understanding the mechanisms by which these
treatments counteract stroke and the therapeutic targets that they act on will
shed new light on possible treatments for stroke.
Transfusion of human umbilical cord blood cells (HUCBC) promotes
neuroprotection and reduces inflammation at the site of injury in the permanent
middle cerebral artery occlusion (MCAO) model of stroke. Injections of cord
blood cells were first used in Parkinson’s, Alzheimer’s and Huntington’s disease
animal models of brain injury and showed increased longevity (Ende and Chen
2001; Ende et al. 2001a; Ende et al. 2001b). Further experimentation of the
intravenous injection of these cells in the stroke animal model resulted in the
improvement of both neurological impairment and motor function deficits (Chen
et al. 2001). Examination of animals subjected MCAO surgery and treated with
HUCBC revealed that these cells migrated to the ipsilateral hemisphere of the
brain and to the spleen (Vendrame et al. 2004). Immunohistochemical
processing of brain sections from HUCBC treated animals revealed less
neurodegeneration and reduced microglial activation when compared to sections
from vehicle treated animals. Biochemical analysis of the brain tissue and the
blood sera revealed reduced NFκB binding activity and a shift to an antiinflammatory IL-10 cytokine profile in HUCBC treated animals when compared to
vehicle controls (Vendrame et al. 2004; Vendrame et al. 2005; Vendrame et al.
2006). Treatment of animals at various timepoints after MCAO demonstrated
that cord blood cells could be transfused up to 48 hours after MCAO and still
continue to cause significant reductions in infarction volume (Newcomb et al.
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2006). This shows that a therapeutic window of treatment can be extended past
the three hour limitation of rtPA and have beneficial effects.
Standard dogma of infarct formation contends that almost immediately
after blockage of blood flow, dysregulation of neuronal homeostasis leads to
necrosis and apoptosis of brain parenchyma. Interestingly many of the cellular
markers for neuronal death such as TUNEL, activated caspase 3, and absence
of Nissl staining are evident at 48 hours post stroke (Newcomb et al. 2006).
Reliance on the aforementioned markers as evidence of apoptotic cell death has
led investigators to begin therapeutic intervention either prior to or rapidly
following stroke onset. Treatment with HUCBC at delayed time points after
MCAO, however, causes reductions in the neurodegenerative labeling of TUNEL
and absence of Nissl staining (Newcomb et al. 2006). This suggests that these
stains are not indicators of cell death, but are instead labeling compromised
neurons. The observation that many of the markers for neuronal loss used by the
scientific community are reversible is extremely controversial. However,
treatment with HUCBC provides evidence that the infarction does not consist of
entirely dead cells at extended time points after stroke but is made up of tissue
that still has the potential of being “rescued” when a neuroprotective and antiinflammatory treatment is given (Newcomb et al. 2006).
To find other agents that work at delayed time points, it is necessary to
choose treatments that work in a similar fashion to HUCBC’s promotion of
neuroprotective and anti-inflammatory effects. Therefore, we chose a sigma
receptor agonist as this drug class has well known neuroprotective and anti-
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inflammatory properties (Bourrie et al. 2002; Goyagi et al. 2001; Katnik et al.
2006; Takahashi et al. 1996; Vagnerova et al. 2006; Zhang and Cuevas 2005).
Sigma receptors are highly dispersed throughout the brain and periphery,
where they bind a vast assortment of substances including neurosteroids,
antipsychotics, antidepressants, phencyclidine (PCP)-related compounds, and
opiates (Bowen 2000; Katnik et al. 2006; Walker et al. 1990). Sigma receptors
are classified into two subtypes based on their pharmacological binding profiles.
Sigma-1 receptors preferentially bind (+) benzomorphans (Walker et al. 1990)and
have been shown to modulate voltage gated potassium channels and IP3
receptor function while sigma-2 receptors preferentially bind ibogaine and alter
voltage gated sodium and calcium channels (Zhang and Cuevas 2002; Zhang
and Cuevas 2005) . Sigma receptors function in several physiological and
pathophysiological processes in the brain including learning and memory,
movement disorders, and drug addiction (Matsumoto et al. 1990; McCracken et
al. 1999; Senda et al. 1996). Importantly, sigma receptor activation has been
shown to be neuroprotective in various stroke models. Previous studies
regarding sigma receptor activation and focal ischemia have focused on the
activation of the sigma-1 receptor (Goyagi et al. 2001; Takahashi et al. 1996).
Voltage gated sodium and calcium channels, which are modulated by sigma-2
receptors, are involved in neuronal excitability and contribute to spreading
depression during stroke (Gribkoff and Winquist 2005). Sigma receptor
activation also leads to potent anti-inflammatory properties. Activation in vivo
enhances lipopolysaccharide-induced systemic release of the anti-inflammatory
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cytokine IL-10 while simultaneously suppressing TNF-α synthesis (Bourrie et al.
2002). We postulated that activation of both the sigma 1 and sigma 2 receptors
would result in better protection of the brain parenchyma than activating only one
of the receptor types. Additionally administration of the sigma ligands in these
studies occurred either prior to stroke or shortly after the insult providing no
insight on the efficacy of these compounds when administered at delayed time
points (Goyagi et al. 2001; Takahashi et al. 1996). Examination of these agents
at delayed time points is important to make treatment more available to
individuals who are not candidates for rtPA.
We designed a series of experiments in which the sigma receptor ligand
DTG was subcutaneously administered 24 hours post MCAO. As seen with
HUCBC treatment, DTG significantly reduced infarct volume, enhanced neuronal
survival, reduce astrogliosis and modulated immune cell responses (Figure 1)
(Ajmo et al. 2006). This observation reinforces the hypothesis that treatment
regimens which are both neuroprotective and anti-inflammatory can reverse or
prevent neurodegenerative processes at delayed time points.
From these experiments, however, it is impossible to discern what
proportion of the observed neuroprotection is due to the anti-inflammatory or the
direct neuroprotective properties of these compounds. Sigma receptors have
been shown to be neuroprotective in vitro by preventing intracellular calcium
dysregulation in cortical neurons during ischemia and up-regulating anti-apoptotic
Bcl family proteins (Katnik et al. 2006). Subsequent studies on transgenic mice
subjected to MCAO however, suggest that the protective effects of sigma
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receptor activation in vivo are mainly a product of its neuroprotective properties
(Vagnerova et al. 2006). In those studies, administration of the sigma-1 receptor
agonist (+) pentazocine to iNOS knockout mice failed to provide significant
decreases in infarct volume when compared to iNOS knockout mice that
received MCAO alone (Vagnerova et al. 2006). Inducible nitric oxide synthase
(iNOS) is an enzyme which is upregulated primarily by microglia and
macrophages during the inflammatory response and produces nitric oxide, a
reactive oxygen species implicated in neuronal death (Virag et al. 2003).
Sigma receptor activation has also been shown to modulate inflammation
in the periphery. These receptors have been identified in organs including
endocrine-related structures, gastrointestinal tract, liver, kidney, and have been
found to be distributed on rat splenocytes. The sigma agonist, SR 31747 is an
immunomodulator that elicits high affinity for sigma receptors expressed on
lymphocytes (Paul et al. 1994). Activation of the these receptors by this agonist
suggests that sigma receptors may be considered as targets for
immunomodulation in that they markedly suppress lipopolysaccharide (LPS)induced production of the inflammatory cytokines interleukin (IL)-1, IL-6, and
tumor necrosis factor-α (TNF-α) in vivo. Conversely, activation with SR 31747
stimulates the production of the anti-inflammatory cytokine IL-10. These reports,
in conjunction with our sigma receptor activation data, suggest that up-regulation
of anti-inflammatory effects coming from the periphery are causing a reduction in
inflammation thereby decreasing neurodegeneration.
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Previous studies with HUCBC treatment for stroke revealed that cord
blood cells migrate to the spleen after ischemic insult (Vendrame et al. 2004).
PCR analysis for human DNA showed that cord blood cell DNA was found only in
the damaged hemisphere of the brain and in the spleen. Identification by human
nuclei immunoreactivity confirmed the presence of HUCBC in this organ
(Vendrame et al. 2004). Further investigation of the effects of HUCBC on MCAO
demonstrated that the spleen shrinks by 50% of its size in response to stroke
alone and transfusion of cord blood cells 24 hours after stroke resulted in spleen
size retention paired with reduced infarct volume at the site of injury (Vendrame
et al. 2006). To substantiate the spleen-related findings from the HUCBC
studies, it was essential to establish splenic reaction to stroke. Therefore, we
chose to remove the spleen from our animal model prior to stroke eliminating this
variable from the overall mechanism that contributes to ischemic injury.
The spleen is secondary lymphoid organ whose function is to filter blood,
store erythrocytes and leukocytes, remove damaged blood cells, and initiate
immune responses (Cesta 2006). The spleen modulates the functions through
its unique internal structure that is composed of red pulp, which filters and stores
the red blood cells, and white pulp, which stores the leukocytes (Brendolan et al.
2007). The spleen’s internal structures are housed by a capsule composed of
dense fibrous tissue, elastic fibers and smooth muscle (Cesta 2006). In times of
physiological stress, smooth muscle of the spleen contracts giving it the ability to
autotransfuse a large quantity of blood cells into the circulation for the purpose of
increasing oxygen transport to afflicted areas (Stewart and McKenzie 2002).
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This is consistent with studies that have shown that the spleen shrinks and
releases splenocytes into the circulation in response to neurodegenerative
diseases (Benner et al. 2004; Offner et al. 2006b).
As seen with HUCBC and DTG treatment, splenectomy prior to stroke
significantly reduced infarct volume, decreased activated microglia/macrophages,
and significantly reduced peripheral neutrophil presence (Figure 2). These
findings support the hypothesis that the spleen contributes to stroke-induced
neurodegeneration and is a part of the overall mechanism of stroke. These data
suggest that activated microglia are not the major contributors of the second
wave of neurodegeneration within the infarction as these cells have been shown
to outnumber infiltrating macrophages (Liu and Hong 2003; Schilling et al. 2003).
Our results are supported by the systemic inhibition of macrophages by antiCD11b, anti-CD18, anti-ED1 and anti-Mac-1 monoclonal antibodies 1 hour after
transient MCAO, which show significant reduction of infarction volume in the
ischemic brain (Chen et al. 1994; Chopp et al. 1994; Zhang et al. 1995b). We
now suggest that there is a strong synergistic effect between activated microglia
and the infiltrating macrophages and neutrophils. Diminishing of the peripheral
immune response by deletion of a population of macrophages, neutrophils, T
cells and B cells through splenectomy dramatically reduces infarction by
decreasing cellular interaction with activated microglia at the site of injury.
Splenectomy prior to stroke also indicates that the majority neutrophils infiltrating
the infarction are of splenic origin. Staining for myeoperoxidase (MPO), a
peroxidase enzyme found in lysosomes of these cells, showed little or no cellular
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presence in brain sections of animals whose spleens were removed prior to
stroke.
While removal of the spleen validated the organ’s involvement in stroke,
these experiments gave no insight to the signaling mechanism connecting the
brain and the spleen at the time of injury. As stated previously, the spleen is
encased in a layer of smooth muscle which can contract to autotransfuse the
circulation with a large amount of blood cells in response to stress (Stewart and
McKenzie 2002). Intuitively, smooth muscle contraction is a function of
adrenergic receptor activation. Therefore, we hypothesized that spleen
shrinkage and inflammatory cell release in response to the stress of stroke is a
function of autonomic neurotransmission. Clinical and experimental studies have
indicated that autonomic nervous system dysfunction is a complication of stroke
(Meyer et al. 2004). Early mortality in stroke patients is associated with cardiac
arrhythmias and myocardial damage (Tokgozoglu et al. 1999; Wang et al. 1997).
It has also been documented that norepinephrine, epinephrine, and blood
pressure all significantly rise after stroke, indicating that sympathetic tone
becomes elevated (Meyer et al. 2004). Interestingly the splenic nerve contains
approximately 98% sympathetic nerve fibers (Klein et al. 1982), and most studies
suggest that the innervation of the spleen is predominantly sympathetic (Elenkov
et al. 2000).
To confirm sympathetic neurotransmission as the signaling mechanism to
the spleen during stroke, we removed neuronal innervation to the organ prior to
MCAO (Figure 3). We speculated that denervation would mimic the effects of
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splenectomy. What we found, however, was that splenic denervation had no
effects on stroke pathology. Sections from the brains of rats whose spleens had
been denervated prior to stroke showed no decrease in infarct volume and
continued to show spleen shrinkage in contrast to sections from the brains of rats
treated with MCAO only. Comparing tissue from denervated rats to MCAO-only
rats showed an up-regulation of activated microglia/macrophages and infiltration
of neutrophils. Flow cytometry analysis of spleen tissue for different molecular
markers of leukocytes resulted only in a significant increase of macrophages in
denervated spleens. The β2 adrenergic receptors are highly expressed in the
membranes of blood monocytes and receptor activation by an agonist has been
shown to be anti-inflammatory by inhibition of proinflammatory cytokine release
and down regulation of intracellular monocyte adhesion molecules (Kuroki et al.
2004; Mizuno et al. 2005). This suggests that removal of sympathetic innervation
to the spleen suppresses anti-inflammatory effects of β2 agonist receptor
activation allowing for the potential increased proliferation of macrophages
observed in the spleen. Denervation of the spleen may also systemically signal
an injury to the organ resulting in the increased proliferation of blood monocytes.
Based on these observations it would appear that splenic reaction to
stroke is not dependent on direct innervation. The bulk release of epinephrine
and norepinephrine are from the adrenal gland and are released into the
circulation during times of intense physiological stress (Rosol et al. 2001; Wong
2006). These adrenergic agonists could still activate the α adrenergic receptors
of the smooth muscle capsule surrounding the spleen causing contraction
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resulting in the observed organ shrinkage. Investigation of denervation of spleen
prior to stroke will need to be carried out to 96 hours after injury to truly
determine if direct sympathetic neurotransmission by the splenic nerve causes
enhanced neurodegeneration. Time course experiments of stroke and
transfusion of HUCBC showed that infarct damage can be reversed at 96 hours
after MCAO when treated at 48 hours with cord blood cells (Newcomb et al.
2006). This showed that neurons in this animal model are severely
compromised at this time but still have the potential of recovery. While we see
increased neurodegeneration at 48 hours after stroke, denervation may dampen
signal transmission enough to allow compromised nerves to be rescued.
The conclusion of these experiments has led to the deliberation of several
avenues for the further investigation of the alternative targets examined in this
study. While it has been shown that the spleen contributes to stroke-induced
neurodegeneration, investigation into which specific cell types leave the spleen,
migrate to the site of injury, and induce the most damage would aid in the
development of a treatment that could be administered which blocks those cells.
This would be markedly less invasive compared to splenectomy. Cellular
migration could be examined by the labeling of cells directly in the spleen and
then subjecting the animal model to stroke. While not shown in the above
experiments we have gathered data showing that monocyte labeling in the
spleen with fluorescent carboxyfluorescein diacetate succinimidyl ester (CFSE)
can be detected in brain tissue at delayed time points after stroke. Double
immunohistochemical staining of the brain tissue of animals whose spleens were
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removed prior to stroke compared to animals subjected to stroke only could
identify the different splenic cell types that are infiltrating the brain. Another
possible experiment is to remove the spleen prior to stroke, culture splenocytes,
separate the cell types and reinsert these individual cell populations back into the
animal after stroke. Separation of cell population could be done by magnetic
absorbents. Magnetic absorbents attach to specific surface molecular markers
found on the cells of interested and then are isolated from the stock solution of
cells by application of a magnetic source (Franzreb et al. 2006). A potential
pitfall of this experiment could arise from the culture of the cells. Cells removed
from the system and cultured could potentially activate in response to
environment changes. Reinsertion of these cells could lead to increased
damage skewing results.

Based on the experimental results of denervation of the spleen prior to
stroke, we need to consider the actions of chemical mediators as modulators of
splenic contribution to neurodegeneration resulting from stroke. Monocyte
chemoattractant protein-1 (MCP-1) has been shown to be a strong starting point
for the mechanisms responsible for the in vivo migration of HUCBC to the brain
after the induction of stroke (Newman et al. 2005). MCP-1 released into the
circulation from the brain may also be the cause of the observed migration of
HUCBC to the spleen (Newman et al. 2005). MCP-1 expression has been
detected in astrocytes and microglia at six hours after ischemic insult and
remains elevated from twelve to forty-eight hours (Huang et al. 2006; Wang et al.
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1995). This chemokine is also detectable in macrophages within ischemic tissue
four days after MCAO (Gourmala et al. 1997). Overexpression of MCP-1 in
MBP-JE transgenic mice lead to increased migration of monocytes and
increased brain infarction size in stroke-induced by MCAO (Chen et al. 2003).
MCP-1 deficient mice also show decreases in infarct volume after MCAO
(Hughes et al. 2002). This suggests that high levels of chemoattractants are
circulating in the blood stream, potentially being filtered by the spleen and
drawing splenic inflammatory cells to the site of injury. Suppression of this
chemoattractant during stroke may show spleen size retention along with infarct
reduction suggesting that splenic reaction to stroke is dependent on chemical
mediators.
Overall we have provided evidence of novel treatments and targets for
stroke by promoting neuroprotection and anti-inflammation, expanding the
therapeutic window of treatment and promoting further understanding of a total
mechanism of stroke. These components must be taken into account in the
development of a universal treatment of stroke for use in a clinical setting.
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Discussion, Figure 19
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Figure 1: Summary schematic of the effects of DTG on MCAO when
administered 24 hours after MCAO. Administration of DTG 24 hours after
MCAO results in decreased infarction area by reducing neurodegeneration. It
modulated the immune cell response to stroke by showing reductions in activated
microglia and infiltrating macrophages at the site of injury. DTG mediates
astrocyte activation causing a reducing in astrogliosis and glial scar formation.
These alterations lead to an overall reduction of cell death.
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Discussion, Figure 20
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Figure 2: Summary schematic of the effects of splenectomy prior to MCAO.
Removing the spleen prior to stroke results in modulation of the peripheral
immune response to stroke by decreasing infiltrating neutrophils at the site of
injury. It mediates peripheral and resident inflammatory responses by showing
reductions in activated microglia and infiltrating macrophages. These effects
cause a decrease in neurodegeneration at the site of injury and reduce the
potential cellular death caused by ischemia
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Discussion, Figure 21
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Figure 3: Summary schematic of the effects of denervation of the spleen
prior to MCAO. Denervation of the sympathetic innervation to the spleen prior
to stroke produced no anti-inflammatory or neuroprotective effects in the brain.
Denervation resulted in considerable infarction volume which was analogous with
the infarct volumes observed with MCAO only. Flow cytometry analysis showed
a significant increase of monocytes in homogenates of spleens that had been
denervated by stroke. Removal of sympathetic innervation to the spleen may
cause increased proliferation or inhibition of release of monocytes from the
spleen during MCAO. Chemical signaling mechanisms may be affecting the
spleen at the time of stroke.
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